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Summary 
 
 
Periprosthetic joint infection (PJI) is the major cause of total joint arthroplasty failures and is 
often caused by methicillin-resistant Staphylococcus aureus (MRSA). The ability of these 
bacteria to rapidly acquire resistance against antibiotics has made it nearly impossible to treat 
these persistent infections. The number of novel antibiotics that have successfully completed 
clinical trials has declined rapidly in the last 50 years. The search for novel antibiotics and 
alternative delivery routes is thus of utmost importance. 
 
Entomopathogenic bacteria, living in close association with nematodes, are a potential source 
of novel antibiotics. One such genus, Xenorhabdus, produces a variety of secondary metabolites, 
including antimicrobial compounds. The majority of these compounds are active against 
numerous so-called multidrug resistant pathogens. Antibiotics produced by Xenorhabdus spp. 
may thus be an alternative treatment for PJI. 
 
Numerous drugs fail phase II and III clinical trials due to insolubility, toxicity and instability at 
pharmaceutically active levels. This can be overcome by encapsulating the therapeutic drugs in 
nanoparticles. The polymer poly(DL-lactide-co-glycolide) (PLGA) has significant attention as a 
colloidal drug delivery device and is well-known for its biocompatibility. 
 
In this study, Xenorhabdus khoisanae was screened for the production of novel antibiotics. Three 
antibiotics were isolated from a X. khoisanae culture, two were similar to xenocoumacin-2 and 
one a novel antibiotic with a mass-to-charge ratio of 671, designated rhabdin. Rhabdin is active 
against two clinical strains of S. aureus (including MRSA). The osteogenic and cytotoxic effects 
of rhabdin were evaluated on two populations of rat femora-derived mesenchymal stem cells 
(MSC). Rhabdin was cytotoxic to the bone marrow-derived mesenchymal stem cells (bmMSC) 
at concentrations exceeding 3.5 µg/ml, but had no anti-osteogenic effects. In contrast, rhabdin 
was completely cytotoxic to proximal femur-derived mesenchymal stem cells (pfMSC). 
Vancomycin, traditionally used to treat MRSA, was also evaluated and no cytotoxicity was 
observed in bmMSC or pfMSC, but vancomycin had an anti-osteogenic effect on pfMSC. 
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Vancomycin was encapsulated in PLGA nanoparticles (VNP) by electrospraying. The mean 
hydrodynamic diameter of VNP was 247 nm. The antimicrobial activity of free vancomycin and 
encapsulated vancomycin was compared and VNP showed enhanced antimicrobial activity. 
Vancomycin release was monitored for 10 days and followed first-order release. After10 days, 
only 50% of the encapsulated vancomycin was released from the nanoparticles. 
 
To our knowledge, this is the first study to report on antibiotics produced by X. khoisanae, the 
anti-osteogenic effects of vancomycin and the encapsulation of vancomycin in PLGA 
nanoparticles by electrospraying. 
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Opsomming 
 
Post-chirurgiese infeksie van ‘n prostetiese gewrig is die mees algemene oorsaak vir 
onsuksesvolle totale gewrigs vervangings. Hierdie infeksies word meestal deur metisillien-
weerstandige Staphylococcus aureus (MWSA) veroorsaak. Die vermoeë van hierdie bakterieë 
om vinnige weerstandigheid teen antibiotika op te bou, maak dit bykans onmoonlik om 
weerstandige infeksies te behandel. In die laaste 50 jaar het die aantal antibiotika wat kliniese 
toetse suksesvol voltooi het, vinnig gedaal. Die soektog na unieke en nuwe antibiotika en 
alternatiewe middels is dus van uiterste belang. 
 
Die entomopatogeniese genus, Xenorhabdus, wat in ‘n eng gemeenskaplike verwantskap met 
nematodes leef, is ‘n moontlike bron van unieke antibiotika. Xenorhabdus spp. produseer n 
verskeidenheid sekondêre metaboliete, insluitend antimikrobiese verbindings. Die meederheid 
van hierdie verbindings is teen ‘n verskeidenheid veelvuldige antibiotika-weerstandige 
patogene aktief. Daar, is dus ‘n moontlikheid dat antibiotika van Xenorhabdus spp. as 
behandeling teen prostetiese gewrigs-infeksies kan dien. 
 
As gevolg van onoplaasbaarheid, toksisiteit en onstabiliteit teen farmakologies-aktiewe vlakke, 
misluk veelvuldige antibiotia tydens fase II and III kliniese toetse. Hierdie negatiewe punte kan 
oorkom word deur die terapeutiese middels in nanopartikels te omsluit. Die polimeer “poly(DL- 
lactide-co-glycolide) (PLGA)” geniet baie aandag as ‘n kolloïdale toedieningsisteem en is 
wêreldbekend as ‘n biologies-versoenbare polimeer. 
 
In hierdie studie is Xenorhabdus khoisanae vir die producksie van unieke antibiotika getoets. 
Drie antibiotika is van ‘n X. khoisanae kultuur geïsoleer, twee is soortgelyk aan xenocoumacin- 2 
en een is ‘n unieke verbinding met ‘n massa-tot-lading verhouding van 671, aangewys as 
rhabdin. Rhabdin is aktief teen twee klinies-verwante S. aureus rasse (insluitend MWSA). Die 
osteogeniese en sitotoksiese effek van rhabdin is teen twee populasies van rot femur-afgeleide 
mesenkiem-stamselle (MSS) getoets. Rhabdin is sitotoksies vir beenmurg-afgeleide mesenkiem-
stamselle (bmMSS) teen konsentrasies hoër as 3.5 µg/ml, maar het geen anti-osteogeniese effek 
gehad nie. In teenstelling hiermee, is rhabdin heeltemal toksies vir proksimaal femur-afgeleide 
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mesenkiem-stamselle (MSS). Vankomisien word tradisioneel gebruik om MWSA infeksies te 
behandel en is vir toksisiteit en osetogeniese effek geëvalueer. Geen toksiese effek is 
waargeneem in bmMSS en pfMSS kulture nie, maar vankomisien het wel ‘n antiosteogeniese 
effek teen pfMSS getoon. Vankomisien is in PLGA nanoparticles (VNP) deur middel van 
elektrosproei omsluit. Die hidrodinamiese deursnit van VNP is 247 nm. Die antimikrobiese 
aktiwiteit van vrye vankomisien en PLGA-omsluite vankomisien is vergelyk. Vankomisien 
omsluite partikels het meer antimikrobiese aktiwiteit getoon.. Vankomisien vrystelling is vir 10 
dae gemonitor en het eerste-orde vrystelling getoon. Na 10 dae was 50% van die omsluite 
vankomisien vrygestel. 
 
So ver ons kennis strek is hierdie die eerste studie wat die werking van ‘n antibiotikum, 
geproduseer deur X. khoisanae, raporteer. Hierdie is ook die eerste studie op die anti- 
osteogeniese effek van vankomisien en die omsluiting van vankomisien in ‘n PLGA polimeer deur 
middle van die elektrosproei tegniek. 
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Preface 
 
This thesis is presented as a compilation of manuscripts. Each chapter is introduced 
separately and is written according to the style of the respective journal. 
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General Introduction 
 
 
Osteoarthritis (OA) is a debilitating bone disease that effects 22.7% of the world population 
(1). Treatment varies from following a pharmacologic approach to using complementary and 
alternative medicine and surgery (2). Surgery is only used when pharmacological and 
behavioural treatments failed to improve mobility and alleviate pain (2). Treating OA with 
total joint arthroplasty (TJA) is a well-known technique and delivers excellent results, with 
total hip arthroplasty (THA) being the most popular and successful (3, 4). With a success rate 
of 95%, many might believe that THA failures are a minor issue, but since the major cause of 
failure is infection, this is unfortunately the contrary (5). Periprosthetic joint infection (PJI) is 
defined by the Musculosketal Infection Society (MSIS) as a condition caused when a sinus tract 
(wound tunnel) comes in contact with the prosthesis, the isolation of pathogens, by culture, 
from two separate tissue or fluid samples near the prosthesis, elevated concentrations of C-
reactive protein and serum erythrocyte sedimentation, elevated leukocyte count and the 
presence of purulence in the affected joint (6). In 2008, Pulido and co-authors reported that 
53% of all PJI are caused by methicillin-resistant Staphylococcus spp. (MRS), of which 19% was 
Staphylococcus aureus and 11% Staphylococcus epidermidis. The same authors also reported 
that 11% of PJI was caused by Gram-negative bacteria, with Klebsiella pneumoniae and 
Escherichia coli being the most prevalent (7). Biofilm formation by these bacteria further 
complicates PJI treatment is. Traditionally, methicillin resistant infections were treated with 
vancomycin, but Kirby and co-authors reported in 2010 on the discovery of MRS with reduced 
sensitivity to vancomycin (8). 
 
Although antibiotic resistance has always been an intrinsic part of antibiotic treatment, the 
misuse and over-prescription of antibiotics is contributing to the acceleration seen in 
antibiotic resistance (9). Further aggravating the situation is the decline in the discovery and 
approval of novel antibiotics. For decades, antibiotics have mainly been isolated from a 
handful of soil micro-organisms, including Bacillus, Streptomyces and Pseudomonas species; 
all belonging to the group Actinomycetes (10). This narrow-minded approach has led to the 
exclusion of numerous unique niches with antibiotic potential. One such niche, nematodes 
and their mutualistic bacteria, holds great potential as a possible source for novel antibiotics 
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(10–12). Xenorhabdus spp. co-exist in mutualistic relationship with Steinernema nematodes 
and produce various antimicrobial metabolites, including indole derivatives, iodinine, 
phenethylamides and more complex molecules derived from a hybrid non-ribosomal peptide 
synthetase/peptide polyketide synthase (NRPS/PKS) system (12). 
 
Another reason for the decline in approval of novel antibiotics is that, after going through the 
different phases of clinical evaluations, a large percentage turn out to be toxic, whereas others 
are water-insoluble or unstable (13). Many researchers have shown that these negative 
characteristics can be overcome by incorporating therapeutically active drugs in 
nanoparticles. Recently, Turos and co-authors (14, 15) also reported that the antimicrobial 
activity can be enhanced by encapsulation in nanoparticles. 
 
A novel antibiotic from an entomopathogenic bacterium that engages in a mutualistic 
relationship with a Steinernema jeffreyense nematode, was isolated and partially 
characterised in this study. This new antibiotic with a mass-to-charge ratio of 671 is and was 
evaluated for cytotoxicity in vitro on bone marrow mesenchymal stem cells (bmMSC) and 
proximal femur mesenchymal stem cells (pfMSC). Vancomycin was encapsulated in 
poly(lactide-co-glycolide) (PLGA) nanoparticles to enhance its antibiotic potential. The 
nanoparticles were characterised based on size, morphology and release profile. The 
antibiotic activity was evaluated in vitro against Staphylococcus aureus Xen 31 (methicillin 
resistant) and Xen 36 (methicillin sensitive). 
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Introduction 
 
 
Although micro-organisms are blamed for the majority of diseases that plague humans, they 
produce secondary metabolites that may be developed into antimicrobial compounds (1, 2). 
Antibiotics play a big role in the modern health care industry, saving numerous lives, and have 
become even more important with the rise of HIV/AIDS. Anti-retrovirals improved the life 
expectancy of an HIV/AIDS sufferer by approximately 30 to 40 years (3), but in most cases, 
death is caused by a microbial infection. Resistance to antibiotics is thus a major challenge to 
HIV/AIDS sufferers. 
 
In 1909, Sahachiro Hata, identified arsphenamine, an arsenical compound, that was, 
considered the ‘magic bullet’ for treatment of syphilis (4, 5). Initially known as compound 606, 
arsphenamine was later relabelled as Salvarsan. The next big discovery was made by Alexander 
Fleming in 1928 when he noticed a blue mold, Penicillium notatum, inhibiting the growth of 
Staphylococcus aureus (6). Although Alexander Fleming was not able to demonstrate the 
therapeutic value of penicillin, his research paved the way for the antibiotic era. Many of the 
techniques used by Fleming are still widely used in antibiotic development (7). In August 1940, 
a paper was published by HW Florey and his colleagues demonstrating the therapeutic value 
of Penicillin (8) and by the end of 1943, penicillin was mass produced and used to treat soldiers 
in World War II (7). Sulfonamides, a azo dye derivative, was clinically introduced by Dogmagk 
in 1935 as protonsil, before the wide spread use of penicillin (9, 10). Following the success of 
penicillin Merck invested in the research of a soil scientist, Selman Waksman, who noticed 
that as many as 50% of actinomycetes inhibited the growth of other micro-organisms (11, 12) 
and isolated more than 10 different compounds with antimicrobial activity. Streptomycin, the 
first aminoglycoside isolated from Streptomyces griseus in 1943 and clinically introduced as a 
tuberculosis treatment in 1946, was one of those compounds (7, 13, 14). The discovery of 
streptomycin also led to the first randomized, double-blind, placebo- controlled clinical trials 
throughout Europe (15). 
 
The next 30 years of antibiotic discovery was fruitfull and no less than 8 antibiotic classes were 
discovered, including amphenicols (16–18), polymyxins (19–22), macrolides (23), 
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tetracyclines (24), rifamycins (25, 26), glycopeptides (27), lincosamides (28) and quinolones 
(29). In the last 50, years only seven new classes of antibiotics have been discovered and 
approved by the FDA for human consumption, of which streptogramins and pleuromutilins 
were discovered before the 1970’s (13). The timeline of clinical introduction of the antibiotic 
classes are depicted in Fig. 1. 
 
This golden era of antibiotics was short-lived, because bacteria developed resistance faster 
than new antibiotics were discovered (15). Three factors contributed to the rise in resistance 
and the decline in usable antibiotics: a decline in pharmaceutical investments, are over-use of 
antibiotics and the misuse of antibiotics by the food and agricultural sectors (13, 30). 
 
Since 1970, only seven new classes of antibiotics entered the market, compared to the 11 
novel classes licenced from the 1930s to 1960s (31). This lack in investment is due to various 
reasons, including reduced profit since novel antibiotics are used as last resort, shorter period 
of administration compared to other drugs, generic competitors and regulatory hurdles 
rendering it nearly impossible to obtain FDA approval (13). There are 18 classes of antibiotics 
on the market namely, β-lactams, streptogramins, amphenicols, polymyxins, macrolides, 
Arsenical 
compounds 
(1910) 
Sulfonamides 
(1936) 
ß-Lactams 
(1943/1938) 
Aminoglycoside 
(1946) 
Amphenicols 
(1948) 
Quinolones  
(1968) 
Polymyxins 
(1950) 
Macrolides 
(1951) 
Tetracyclines 
(1952) 
Rifamycins 
(1958) 
Glycopeptides 
(1958) 
Streptogramins 
(1999) 
Oxazolidinones 
(2000) 
Lipopeptides 
(2003) 
Pleuromutilins 
(2007) 
Macrolactones 
(2011) 
Diaryquinolines 
(2012) 
Lincosamides 
(1966) Ridinilazole (2015) 
Fig. 1: Timeline of clinical introduction of antibiotic classes. 
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tetracyclines, rifamycins, glycopeptides, lipopeptides, quinolone, oxazolidinone, 
pleuromutilins, macrolactones, diarylquinoline and ridinilazoles. The majority of these classes 
were isolated from Streptomyces spp. This lack in novel sources for antibiotics and thus limited 
structural diversity, have also contributed to the rise in antibiotic resistance (32).  
 
Another factor contributing to the reduced output of novel antibiotics is the instability, low 
bio-distribution, short-half life and toxicity of natural compounds (33). This can be overcome 
by encapsulating antibiotics in nanoparticles. Numerous researchers have shown that by 
encapsulating pharmaceutically active drugs in nanoparticles, the bio-distribution can be 
improved, half-life prolonged, toxicity decreased, therapeutic effects enhanced and the drug 
protected against in vivo conditions (34–38). 
 
For the past 100 years, soil microbes have been the main source of antibiotics (1). Numerous 
other potential antibiotic producers have been neglected, for example the Burkholderiales 
order, Lysobacter sp. from the Xanthomonadales order and bacteria associated with 
nematodes (1, 2). 
 
Order Burkholderiales 
 
 
The order Burkholderiales belongs to the class β-proteobacteria and contains two genera with 
the potential to be novel sources of antibiotics, namely Burkholderia and Janthinobacterium 
(2). Bacteria from the order Burkholderiales are well known for the production of various 
secondary metabolites, including antifungals and pesticides (39). These species can be isolated 
from various niches. Bacteria from the genus Burkholderia are infamous for nosocomial 
infections and is often isolated from patients with cystic fibrosis (1), but Santos et al. (40), Kang 
et al. (41) and El-Banna et al. (42) have shown that Bulkolderia species have potential as novel 
sources of antimicrobials. The first compounds with broad spectrum antibiotic activity isolated 
from a species of Burkholderia, was enacyloxins (43), originally isolated from Frateuria spp. 
W-315 (44). 
 
The antimicrobial potential of Janthinobacterium spp. was first reported by O’Sullivan and co- 
authors in 1990 (45). Strains from the genus Janthinobacterium are motile Gram-negative 
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bacteria isolated from various niches including the Antarctic, plants and as symbionts of 
amphibians and insects (1). O’Sullivan reported that janthinocins, a peptide lactone antibiotic, 
produced by Janthinobacterium lividum was not only active against Staphylococcus aureus, 
but two to four times more potent that vancomycin. More recently, Graupner and co-authors 
reported the production of jagaricin, a novel cyclic lipopeptide with antifungal properties (46). 
 
Genus Lysobacter 
 
 
Species from the Lysobacter genus are Gram-negative and motile by gliding. They are strictly 
aerobic and produces lytic enzymes (47). The first antibiotic isolated from a Lysobacter sp. was 
cephabacin, classified as a ß-lactam antibiotic. Cephabacin inhibits cell wall synthesis and is 
active against a wide variety of Gram-positives, including ß-lactam resistant bacteria (48). 
 
The cyclic peptides produced by Lysobacter spp. are known for their potent activity against 
methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus. The first cyclic 
peptide, lysobactin, was described by O’Sullivan and co-authors in 1988 (49). This was 
followed by the discovery of WAP-8294A compounds in 1998 by Kato and co-authors (50). 
Kato and co-authors reported that compound WAP-8294A did not only have potent activity 
against MRSA, but was 14 times more potent compared to vancomycin and is undergoing 
phase I and II trials at aRigen, a pharmaceutical company situated in Tokyo (48, 50, 51). Lysocin 
E, an unique cell wall synthesis inhibitor, discovered by a Japanese group in 2015 (52), is known 
for its wide-spread activity against Gram-positive and Gram-negative bacteria by binding to 
menaquinone (52, 53). Tripropeptins, another cyclic peptide produced by Lysobacter spp., was 
first described by Hashizume and co-workers in 2011 (54). Tripropeptins inhibits bacterial cell 
wall biosynthesis and works synergistically with ß-lactams, but is active against ß-lactam 
resistant bacteria (55). 
 
Nematodes 
 
 
Steinernema nematodes are entomopathogenic and synergistically associated with bacterial 
species from the genus Xenorhabdus (56). The nematode-bacterium life cycle is unique and 
involves both symbiotic and pathogenic associations (Fig 2). The Xenorhabdus bacterium is 
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carried in the gut of the infective juvenile nematode. Infective juveniles (IJ) are a specialized 
free-living form of the nematode that search for insect larvae in the soil to prey on and enter 
through the larval haemocoel. Once the IJs infect the insect, Xenorhabdus spp. are released 
into the insect haemolymph to proliferate and produce various secondary metabolites. The 
secondary metabolites produced by the bacteria include hydrolytic exoenzymes, immune 
suppressors and antimicrobial compounds. Hydrolytic exoenzymes are responsible for the 
bioconversion of the insect larva to nutrients used by the nematodes. The IJ then moults into 
third (3J) and fourth (4J) stage juveniles. The juveniles mature into first generation (1G) males 
and females. The 1G nematodes mate and female nematodes lay eggs. The eggs hatch as first- 
stage juveniles (1J) that matures successively into 2J, 3J and 4J juveniles (long life cycle, Fig 2) 
or IJs depending on food supply (short cycle, Fig 2). The 4J stage nematodes mature into 2G 
adults that reproduce by mating and laying eggs. The eggs hatch and replication continue until 
cadaver (host) resources are depleted. Once the resources are depleted, individuals in late 2J 
stages stop feeding and incorporate a pellet of bacteria. The is followed by moulting into pre- 
infective (PJ) and infective juveniles. The nematodes leave the cadaver in search of new prey. 
The antimicrobial compounds prevent secondary infection of the insect larva and retains a 
“sterile” environment within the insect larva. Thus, the nematode provides protection and a 
mode of dispersal to the bacterium, while the bacterium provides the necessary enzymes and 
immune suppressors to the nematode (57). 
 
In 1959, Dutky was the first to report that the bacterial symbiont of Steinernema carpocape 
produced antibiotics (58). Two decades later, the bacterial symbiont of Steinernema 
nematodes was identified as Xenorhabdus. 
 
Only a handful of Xenorhabdus spp., namely X. nematophilia, X. bovienii, X. szentirmaii, X. 
doucetiae and X. budapestensis have been studied for production of antimicrobial 
compounds. Antimicrobials isolated from Xenorhabdus spp. can be divided into four groups of 
metabolites, namely indole derived, mixed peptide-polyketide, pyrrothine and peptides. 
Indoles derivatives were the first antimicrobials isolated and characterized from X. bovienii 
(59). Indole-derived metabolites are active against a broad spectrum of organisms, including 
bacteria, fungi and insects (60). Xenocyloins and nematophin are well-known indole-derived 
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metabolites produced by X. bovienii (61) and X. nematophilia (62), respectively. In 1997, 
Jianxion Li and co-authors reported that the antimicrobial activity of nematophin against 
multidrug resistant S. aureus strains is comparable to the activity of vancomycin (63). 
Xenocoumacins, mixed peptide-polyketide derivatives, a group of antimicrobial compounds 
produced by X. nematophilia that are known to be active against both Gram-positive and - 
negative bacteria (64). Most active secondary metabolites produced by Xenorhabdus spp. are 
classified as peptide metabolites. Xenorhabdus peptide metabolites are either cyclic or linear 
peptides. Cyclic peptide metabolites are produced by X. nematophilia, X. szentirmaii and X. 
doucetiae, and are active against a range of parasites, including Plasmodium falciparum 
(causes malaria) and Trypanosoma brucei (causes sleeping sickness). Linear peptide 
metabolites are more known for their antifungal properties and are produced by 
X. nematophilia and X. budapestensis (2). 
 
 
Most antimicrobial compounds produced by Xenorhabdus spp. have a broad activity 
spectrum. The rise in antibiotic resistant pathogens is a major threat to the health of 
immunocompromised patients. Hospitals are the main breeding ground for antibiotic 
resistant pathogens, thus putting immunocompromised patients at an ever-bigger risk for 
infection by multiple pathogens. The advantage of broad-spectrum antibiotics is that they can 
be used to treat multiple infections at once, thus eliminating the need for multiple 
treatments. 
 
To ensure the longevity of Xenorhabdus antibiotics, they can also be encapsulated in colloidal 
drug delivery systems. These systems can be used to target a specific site of infection, thus 
decreasing the spread of antibiotic resistance and cytotoxicity. Nanofibers loaded with 
antibiotics can be used as bandages to treat severe burn wounds (65), while nanoparticles 
can be prophylactically used in prostheses (66). 
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Nanotechnology: 
 
 
Since the start of modern medicine in the 1700s, a number of so called “incurable diseases” 
and plagues have been treated and in many cases completely eradicated, e.g. small pox (67, 
68). For decades, the focus has been on the development of drugs to cure medically important 
and life-threatening infections, but with the rise in multidrug resistance, it has become clear 
Short life-cycle 
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2G 
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Food scarce 
1G 
F 
IJ 1J  4J 
H G 
PJ 1J  2J 
long life-cycle 
Fig. 2: Diagram of the life-cycle of Steinernema nematodes, illustrating the various life-stages of a 
nematode in a food limiting environment (top) and food rich environment (bottom). A) Infective 
juvenile (IJ) searches for prey and enters host through haemocoel. B) Bacteria are released and C) 
IJ moults into third-stage (3J) and fourth-stage (4J) juveniles. D) Juveniles mature into first 
generation (1G) males and females. The 1G adults mate and females lay eggs, that hatch as first-
stage juveniles (1J). E) If food supply is insufficient 1J moult into IJ, leave the cadaver and hunt for 
new prey. F) Eggs hatch into first stage juveniles (1J) that successively mature into second- stage 
(2J), 3J and 4J juveniles. G) The juveniles mature into second generation (2G) adults, mate and lay 
eggs. Depending on food supply cycle is repeated or (H) 2J moult into pre-infective juveniles 
(PJ), that mature into IJ and exit the depleted cadaver. 
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that alternative drugs and novel delivery systems are required to reach target sites (33). Oral 
and intravenous administration of drugs are still the norm, but with the advances in material 
sciences and nanotechnology, this may soon change (69). Some of the latest techniques 
include transdermal, transmucosal, ocular and pulmonary administration of drugs with 
nanoparticle delivery systems constructed from polymers, metals, carbon-based and silicon- 
based materials (69). Drugs delivered to target sites in an encapsulated form are then released 
from the nanoparticles by diffusion, change in osmotic pressure or disintegration of the 
particles (70). Erodible drug delivery devices are preferred since they eliminate the need for 
device retrieval. 
 
History 
 
 
Since the first experiments on nanoparticles in the 1960s, nanotechnology has revolutionized 
modern medicine (37, 71). In 1964, Alec Bangham and his colleagues published the first article 
on lipid vesicles, now known as liposomes (37, 72–74). This discovery opened the gateway for 
other research groups in the nanotechnology drug-delivery field. The major breakthroughs in 
nanoparticle-based drug delivery are listed in Fig. 3. Robert Langer and Judah Folkman 
developed the first polymer drug-delivery system in 1976 (75), when they produced 
macromolecules from ethylene-vinyl acetate, hydron and polyvinyl alcohol (75). Today, many 
research groups still use polyvinyl alcohol as a drug carrier (76).  
 
Dendrimers, a unique class of polymers, were first described in 1978 by Fritz Vogtle. A 
dendrimer is a nano-sized, monodispersed, radially symmetric molecule consisting of tree-like 
branches (77). With the advances in materials science, more advanced drug delivery systems 
for targeted delivery have been developed. In 1980, two independent research groups led by 
Shinitzky and Weinstein, constructed the first liposome used in targeted delivery (37). The 
Shinitzky group used the pH difference between healthy and cancerous cells to elicit a targeted 
release of the encapsulated drugs (78), whereas the Weinstein group coupled site- directed 
monoclonal antibodies to the outer layer of the liposome (79). Despite the advances made in 
this field, the short half-life of liposomes made this method of drug delivery less optimal. This 
led to the production of PEGylated liposomes, later relabelled as “stealth liposomes”. 
PEGylated liposomes are produced by coupling polyethylene glycol (PEG) to the outer layer
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of the liposome (80). PEGylation increased the half-life of liposomes and polymeric 
nanoparticles. Building onto this, a liposome conjugated with the anticancer drug doxorubicin 
was developed and named Doxil® (81). This was the first FDA-approved nanoparticle and 
paved the way for the approval of many other drug nanocarriers. Since then, more than 50 drug 
nanocarriers developed for various infections, cancer and degenerative eye diseases, have 
been approved by the FDA (82). 
 
With all the advances made in drug-delivery systems, the only shortcoming was the route of 
administration. In 1998, Henry and co-workers (83, 84) designed a microneedle consisting of 
a patch of needles with a radius curvature smaller than 1 µm and 150 µm in length. This device 
allowed pain-free administration of drugs through all three layers of the human skin (83, 84). 
In 1999, Discher and co-workers (85) reported a new group of polymer vesicle with enhanced 
controlled drug-delivery, which they referred to as a polymersome. Amphiphilic block 
copolymers were used to construct the vesicles (85, 86). 
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Fig. 3: Major breakthroughs in nanoparticle-based drug delivery.  
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One of the major drawbacks of nanotechnology-based drug delivery is the inability to mass 
produce uniform particles. In 2005, a new method referred to as Particle Replication in Non- 
wetting Templates (PRINT) was introduced (87). PRINT is based on soft lithography and 
produces nanoparticles with a narrow size and shape distribution. Five years later, the 
dendrimersomes were developed. These nano-vesicles are prepared using amphiphilic Janus 
dendrimers (88). Today, nanomedicine has an impact on all forms of medicine and even plays 
a role in vaccine development. Research groups from across the world are exploring the idea 
of using gold nanoparticles in the delivery of vaccines. The particles are small enough to cross 
the blood-brain barrier, which allows, site-directed delivery of vaccines to brain tissue (89– 
91). 
 
 
Types of nanoparticles 
 
 
Nanoparticles are defined as small particles that act as a unit in terms of properties and 
transport, each with a diameter less than 1000 nm and prepared from a variety of materials 
(92, 93). Depending on the shape, size and chemical properties, nanoparticles are classified as 
fullerenes, solid lipid nanoparticles, liposomes, nanoshells, quantum dots, metallic and 
inorganic nanoparticles, dendrimers, dendrimersomes, micelles, nanocrystals or polymer 
nanoparticles (94, 95). 
 
Fullerenes 
 
 
Fullerenes are hollow spheres, ellipsoids or tubes constructed from carbon atoms (maximum 
300) and are similar in structure to graphite (93). Fullerenes are produced by vaporising 
graphite and collecting the by-product (96). Carbon atoms are arranged to form pentagonal, 
hexagonal or heptagonal rings. Two separate studies have shown that C60 fullerenes (which 
are the most abundant form) have pharmaceutically important properties (95). Friedman and 
co-workers (97) demonstrated the antiviral activity of C60 fullerenes by showing its interaction 
with the active site of the human immunodeficiency virus 1 protease (HIVP). In another study, 
Yamakoshi and co-workers (32) reported on the antimicrobial activity of C60 fullerenes and 
attributed this to the formation of reactive oxygen species. 
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Solid Lipid Nanoparticles 
 
 
The first solid lipid nanoparticles (SLPs) were reported in the early 1990s. These particles are 
50 to 1000nm in size and consist of a solid lipid core and a surfactant as emulsifier (93, 95, 98). 
The small size, large surface-to-area ratio, stability and vast range of lipids to choose from (fatty 
acids, triglycerides, steroids and waxes) made the construction of particles with unique 
properties possible (93). Soybean lecithin, phosphatidylcholine, poloxamer 188, sodium 
cholate and sodium glycocholate are just some of the surfactants that are used to produce 
SLPs (93, 98). A variety of different methods are used for the production of SLPs, namely spray-
drying, ultra-sonication, microemulsion and high-pressure homogenization (93, 98, 99). SLPs 
have gained significant popularity as a colloidal drug-delivery system. This is due to the use of 
physiological lipids, high entrapment efficiency, no need for organic solvents during 
production and improved bioavailability compared to other nanoparticles. Furthermore, SLP 
particles are used to encapsulate hydrophobic and hydrophilic drugs and are easy to mass 
produce and sterilize (38, 93, 98). Despite these positive attributes, SLPs gelatinize under 
certain conditions, changing the polymorphic characteristics of the SLP (95, 99). 
 
Liposomes 
 
 
The first liposomal-like structure was reported by Alec Bangham in 1965 (37, 72, 73). 
Liposomes are defined as small spherical vesicals, ranging from 15 nm to several µm in size 
and with an aqueous core surrounded by phospholipids. The phospholipids form a lipid bilayer 
due to their hydrophobic and hydrophilic properties (38, 93, 95). Liposomes are classified as 
either unilamellar, consisting of a single phospholipid bilayer, or multilamellar (98). The 
inherent properties of liposomes render them ideal carriers of hydrophobic and hydrophilic 
drugs. Liposomes fuse with cell membranes and release drugs intracellularly. Furthermore, a 
range of ‘stealth’ molecules are easily added to the surface of liposomes (38, 93). The only 
major disadvantage of liposomes is their relatively short shelf life, making long-term storage 
impossible (95). Techniques used to produce liposomes include thin-film hydration, reverse 
phase evaporation, solvent injection and lastly detergent dialysis (98). Doxil® was the first 
liposome based drug approved by the FDA for medical use (81).
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Nanoshells 
 
 
Nanoshells are spherical dielectric cores surrounded by a thin layer of metal, usually between 
1 and 20 nm in diameter (93, 100, 101). The dielectric core normally consists of silica or 
polystyrene, while the shell is often gold (93, 100, 101). Nanoshells are highly functional and 
show improved function compared to single composite particles of the same size (93). The 
properties of nanoshells can be modified as desired by changing the constituent material and 
core-to-shell ratio. Although nanoshells can be used for drug delivery their; optical, chemical 
and thermal properties render them ideal in bioimaging and biosensing applications (101). By 
altering the shell thickness, the optical properties are altered, as observed with a shift in 
wavelength from visible to invisible (UV) on the electromagnetic spectrum. Encapsulating the 
nanoshells in silica forms a multishell with three layers (silica-gold-silica), which improves the 
thermal stability of the nanoshells. The surface chemical properties of some nanoshells are 
altered by coating the gold outer shell with a material of desired properties (101).  
 
In a study done by Mirkin et al. (102), DNA was immobilised on gold nanoshells and used to 
detect the presence of complementary DNA strands in a biological environment. Antibodies 
specific for a disease or tumour can also be immobilised on gold or metal nanoshells. Once the 
nanoshells are inserted into the body, they bind with the specific diseased cells and are 
detected with lasers (93, 101).  
 
Nanoshell synthesis is a complicated two-step process. Various techniques have been 
developed to synthesise the core structure of nanoshells, e.g. precipitation, micro emulsion, 
sol-gel condensation, grafted polymerization and layer-by-layer absorption (101). To ensure a 
homogeneous coating (shell), the surface of the core is first coated with a primer (coupling 
agent). That enhances the coupling of the shell material with the core material (103). Although 
many advances have been made, nanoshell technology still has a long way to go in regard to 
synthesis. 
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Quantum dots 
 
 
Quantum dots are defined as a group of heterogeneous nanoparticles consisting of a 
semiconductor nanocrystal, or core, containing an interface between different semiconductor 
materials (93). Their size ranges between 2 and 100 nm depending on the thickness of the 
coating (71). Originally quantum dots consisted of Cadmium-Selemide (CdSe), but an 
alternative material had to be used because of the cytotoxicity of Cd. This led to the 
development of quantum dots consisting of a Copper-Indium-Sulphide (CuInS2) core (104). 
Due to the small size of quantum dots, they possess unique photostable properties rendering 
them perfect for bioimaging (82). However, before quantum dots can be used in a clinical 
setup, more research on cytotoxicity needs to be done (71). 
 
Inorganic nanoparticles 
 
 
Metallic nanoparticles consist of a metal that exhibits antibacterial activity. Silver has been 
known for its antibacterial properties since ancient times and have been used by the medical 
industry for centuries (38). Metal nanoparticles have various shapes and sizes ranging 
between 10 and 100 nm. These nanoparticles are produced by physical methods, which 
include electrochemical reduction, solution irradiation, spark discharging and cryochemical 
synthesis (95). Traditionally, metal oxide nanoparticles, such as Zinc Oxide (ZnO), were used 
as drug carriers, but it was recently discovered that these nanoparticles are also active against 
pathogenic Escherichia coli (105). Titanium Oxide (TiO2) particles are other metal oxide 
nanoparticles well-known for their antibacterial activity (38). Superparamagnetic iron oxide 
particles (SPIONS) are defined as particles (5 – 100 nm in diameter) attracted to a magnetic 
field, but which do not retain residual magnetism once the magnetic field is removed. The 
unique paramagnetic property of SPIONS renders them ideal to be used in MRI imaging and 
controlled drug release. To date, eight different inorganic nanoparticles have been approved 
by the FDA for clinical use. Five of these are used as an iron supplement, two as an imaging 
agent and one to treat glioblastoma (Table 2) (82). 
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Dendrimers and dendrimersomes 
 
 
Dendrimers are a unique group of highly branched, unimolecular and monodispersed polymer 
nanoparticles. Dendrimers are between 1 and 20 nm in diameter and are known for their well-
defined branches (69, 71, 93). Dendrimers consist of three distinct structures, namely the 
core, containing the drug, layers of polymer branches and functional end groups on the outer 
layers of the branches (77, 93). Convergent and divergent step growth polymerization are used 
to synthesize the branches, while the drug molecules can be incorporated either via 
encapsulation or complexation (69, 77). Hydrophobic and hydrophilic drugs can be 
incorporated in dendrimers rendering them ideal drug delivery vehicles. Furthermore, the 
large surface area-to-size ratio ensures optimal release of the incorporated drugs (38). The 
first dendrimer consisted of polyamidoamine (PAMAM), but the toxicity of the polymer made 
it unsuitable for use in a clinical setting. However, by modifying the terminal ends of PAMAM, 
the cytotoxicity has been greatly reduced (38). A new group of dendrimers, dendrimersomes, 
are nanosized vesicles consisting out of Janus dendrimers (88). Janus dendrimers are synthetic 
amphiphilic dendrimers with two dendrimeric wedges terminated by different functional 
groups at their terminals (106). This allows the dendrimersome to interact with multiple 
cellular targets. The defined structure, monodispersed size, stability and functionalization of 
terminal ends makes dendrimers and dendrimersomes ideal for targeted drug delivery (69). 
 
Micelles 
 
 
Micelles are aggregates of surfactant molecules/amphiphilic block copolymers that self-
assemble in aqueous solutions to form a hydrophobic core. Although they are similar in 
structure to liposomes, they are more stable and thus better suited for controlled drug release 
(82, 107). By balancing the hydrophobic and hydrophilic ends of the copolymers in the 
amphiphile, the size and morphology of micelles can easily be controlled (82) Micelles range 
from 1 to 50 nm in size, depending on the type of block copolymer used. Due to the 
hydrophobic core of micelles, they can be used to entrap poorly water-soluble drugs, while 
the amphiphilic exterior promotes dissolution of the drug (108). Micelles are produced using 
one of two methods depending on the hydrophobicity of the copolymer. The direct dissolution 
method is used for water soluble polymers, whilst oil-in-water emulsification is used for  a 
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water insoluble polymer (107). The outer surface of a micelle is formed by constructing 
micelles from a variety of end-functionalized block copolymers (109). Currently, a number of 
micelles are being subjected to clinical trials (82). 
 
Nanocrystals 
 
 
Nanocrystals are defined as nanoparticles with a crystalline structure, solely composed of the 
active drug (82, 110). The increased surface area-to-size ratio compared to the free drug 
increases the dissolution velocity and saturation stability of pharmaceutical drugs (82). A big 
disadvantage of nanocrystals is that they need to be stabilized with additives (110). One of 
three methods can be used to synthesise nanocrystals, namely precipitation, milling and 
homogenization. The precipitation method was developed by Sucker for the preparation of 
hydrosols (111). In this method, the drug is dissolved in a solvent, the solution is then added 
to a nonsolvent, leading to precipitation of nanocrystals. Disadvantages of using this method 
are that a stabilizer needs to be added and residues of the organic solvent and surfactant are 
detected in the sample (110).  
 
Milling is a more robust method and uses ball mills to reduce the size of nanocrystals. The ball 
mills are typically made from stainless steel, glass, ceramics or highly crosslinked polystyrene. 
Although the milling process is slow and only small batches of nanocrystals can be synthesized, 
the FDA has approved four nanocrystals for clinical use.  
 
The homogenization methods for nanocrystal synthesis use high pressure and shear force to 
reduce the size of the particles. Various different technologies are used to synthesis 
nanocrystals via homogenization. Microfluidizer technology, developed by Bruno and 
McIlwrick in 1999, generates small particles via frontal collision of two fluid streams under 
high pressure. Piston gap homogenization in water (Dissocubes® technology), developed by 
Müller and co-workers, forces the drug through a homogenization gap with pressures up to 
4000 bar (112). This increases the dynamic pressure of the solution, which is compensated for 
by reducing the static pressure below the vapor pressure of the solution, resulting in the 
formation of gas bubbles. Once the solution has passed through the gap, the bubble collapses 
due to the lowering in pressure. Shockwaves are generated by the formation and implosion of 
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the bubbles. The shear forces generated, turbulent flow and the power of the shockwaves 
reduce the size of the drug particles (113).  
 
The last technology, Nanopure® technology, is also based on the piston gap homogenizer and 
was developed by Pharma Sol GmbH. Instead of using water as with Dissocubes® technology, 
Nanopure® technology uses a dispersion medium with a low vapor pressure to generate 
nanocrystals (112). Although homogenization is universally applicable and a rapid method, it 
is energy intensive and experience is needed to operate the machinery (110). 
 
Polymer nanoparticles 
 
 
Polymer nanoparticles are the most widely used and studied and are defined as particles with 
diameter less than 1000 nm consisting of either natural or synthetic polymers (92). A wide 
variety of polymers can be used for the synthesis of polymeric nanoparticles and the polymer 
type has an enormous influence on the structure, possible applications and physio- chemical 
properties of the particles. These polymers can be divided into two groups, natural and 
synthetic polymers. Although natural polymers are not as widely used as synthetic polymers, 
they are still important to keep in mind (92).  
 
Polymer nanoparticles are constructed of various polymeric materials, including two natural 
polymers, chitosan and gelatin, or 5 groups of synthetic polymers, poly(esters), poly(ortho 
esters), poly(anhydrides), poly(amides) and polyphosphazenes (Refer to Table 1 for the 
structures of the synthetic polymers). Polymers used in controlled drug delivery vehicles have 
to be biodegradable and form small, water-labile, nontoxic products during degradation. The 
erosion rate must be easily adjustable by manipulating the backbone of the polymer, and 
directly linked to the release rate (114). 
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Natural polymers 
 
Chitosan 
 
Chitosan is a natural carbohydrate derived from chitin, the main component of the 
exoskeleton in crustaceans, and is isolated by decolourization of the shell with potassium 
permanganate followed by boiling in NaOH to N-deacetylate the chitin (115–117). Chitosan 
was first discovered by Rouget in 1859, but formally named by Hoppe-Seyler in 1894 (117, 
118). Due to the low production costs, FDA approval, biodegradability and biocompatibility, 
the use of chitosan in the medical and food industries has increased immensely over the last 
two decades (119). Chitosan nanoparticles can be synthesised by ionotropic gelation, 
microemulsion, emulsification solvent diffusion, polyelectrolyte complex (PEC), 
emulsification-cross linking, complex coacervation, solvent evaporation or coprecipitation 
(116, 117). 
 
Ionotropic gelation is based on the electrostatic interactions between the amine groups of 
chitosan and negatively charged polyanion groups. In short, chitosan is dissolved in acetic acid, 
followed by the addition of a polyanion or an anionic polymer (120, 121). Microemulsion is a 
more complex method. Firstly, a surfactant is dissolved in hexane, followed by the addition of 
chitosan dissolved in acetic acid and glutaraldehyde. The solution is stirred overnight at room 
temperature (25℃). After 24 h hexane is allowed to evaporate, and excess surfactant is 
removed by precipitation. Nanoparticles are collected via centrifugation, dialysis and 
lyophilization (122, 123).  
 
The emulsification solvent diffusion method is only suitable for hydrophobic drugs. For this 
method, an organic phase is injected into chitosan dissolved in acetic acid containing a 
stabilizer. The polymer formation is obtained by diluting the organic phase with water under 
mechanical stirring and high-pressure homogenization, leading to particle precipitation (122, 
124). Synthesis via the PEC method is also based on electrostatic interactions between anions 
and the cationic polymer (chitosan). This method is preferred because it is simple, lacks any 
harsh conditions and the formation of the nanoparticles is spontaneous (118, 125). The 
emulsification-cross linking method is used to encapsulate water-soluble drugs. Nanoparticles 
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are produced by adding dioctyl sodium sulfosuccinate (AOT) to a sodium Alg (a biodegradable 
co-polymer of mannuronic acid and guluronic acid) solution, followed by vortexing the 
solution and emulsification over an ice bath. Polyvinyl alcohol (PVA) is then added and 
emulsified by sonication, followed by the addition of an aqueous calcium chloride solution. 
Methylene chloride is allowed to evaporate and nanoparticles are collected with 
ultracentrifugation, washing and lyophilization (126, 127).  
 
The complex coacervation method is used for the production of chitosan-DNA nanoparticles. 
Chitosan-DNA nanoparticles are produced by vortexing a heated solution of chitosan 
(dissolved in acetic acid) and plasmid DNA (pDNA, dissolved in sodium sulphate/dextran 
sulphate) (128, 129). The solvent-evaporation method is also used to produce chitosan-DNA 
nanoparticles. Briefly, chitosan is dissolved in ethanol and added to a poly-L-lisin solution 
(dissolved in ethanol) and mixed, followed by the addition of pDNA-Tris buffer. Ethanol is 
allowed to evaporate under reduced pressure and nanoparticles are collected (128). Chitosan-
Alg nanoparticles have also been produced by the solvent evaporation method to encapsulate 
antibiotics. Coprecipitation is used to produce lactic acid-grafted chitosan nanoparticles. This 
method produces nanoparticles with a high degree of uniformity and has a high encapsulation 
efficiency. To produce lactic acid-grafted chitosan nanoparticles, chitosan dissolved in lactic 
acid is dehydrated using ammonium hydroxide (130). 
 
Chitosan nanoparticles has numerous applications in the medical industry, including 
intravenous delivery of anticancer drugs, oral delivery of numerous drugs, delivery of DNA 
(119), vaccines (131), ocular drugs and drugs destined for the brain and lastly to carry and 
protect insulin (117). 
 
Gelatin 
 
 
Gelatin, well known for its use in the food industry, is obtained by partial alkaline or acid 
hydrolysis of animal collagen and is defined as a polyampholyte with cationic, anionic and 
hydrophilic groups (132, 133). Gelatin is a promising drug carrier due to its biocompatibility 
(non-toxicity), biodegradability, abundance and low production cost. Commercial gelatin is 
available in two forms (type A and type B) depending on the hydrolysis method used. Type 
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A is produced when collagen is treated with acid, while type B gelatin is produced when 
collagen is treated with alkali (134). In the past, gelatin has been used in the medical industry 
as a plasma extender and stabilizer (133). As in the case for chitosan nanoparticles, 
numerous methods exist for the synthesis of gelatin nanoparticles, namely two-step 
desolvation, simple coacervation, solvent evaporation, microemulsion, nanoprecipitation 
and self-assembly through chemical modifications (132, 135). Many of the synthesis 
techniques used for gelatin nanoparticles are similar to those used to synthesis chitosan 
nanoparticles. Thus, only the methods unique to gelatin nanoparticle production, namely 
two-step desolvation, nanoprecipitation and self-assembly through chemical modifications, 
will be further discussed. 
 
Two-step desolvation, also referred to simply as desolvation, is a thermodynamic driven 
process (136). The nanoparticles are formed when a desolvation agent is added to a gelatin 
solution. The desolvation agent dehydrates the gelatine, inducing a conformational change. 
This step is repeated to ensure the formation of uniform nanoparticles. This is followed by a 
cross-linking step to harden the particles (135). In 2010, Ofokansi and co-workers developed 
a simpler one step desolvation method, in which it is no longer necessary to repeat the initial 
desolvation step (137). Although desolvation is a commonly used method, two disadvantages 
are associated with the method namely, the use of organic solvents and toxic crosslinkers 
(135). Nanoprecipitation, also known as solvent displacement, is a well-known technique in 
the polymeric nanoparticles field and is used to produce both natural and synthetic polymer 
nanoparticles (132, 138). Nanoprecipitation is a favourable method for the production of 
gelatin nanoparticles since it produces nanoparticles of a uniform size, is simple and easy to 
use and not energy intensive. The nanoparticles are produced by adding gelatin (dissolved in 
water) and the drug to ethanol containing poloxamer as a stabiliser, followed by the addition 
of glutaraldehyde as a crosslinking agent (132, 135). The final method, self-assembly through 
chemical modification, was first proposed by Kim and Byun in 1999. The authors proposed 
PEGylating gelatin, by coupling the carboxyl groups of deoxycholic acid (DOCA) and 
carboxylated monomethoxy polyethylene glycol (MPEG) to the amine groups of gelatin to 
form gelatin micelle like nanospheres. The self-assembled nanoparticles form when the 
gelatin/DOCA/MPEG solution is sonicated (132, 135, 139). 
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Synthetic polymer 
 
Poly(ester) 
 
Poly(ester) polymers are a group of biodegradable polymers produced when the ring 
structures of lactones and lactides are broken by either cationic of metalorganic catalysed 
polymerization, also known as ring-opening polymerization (ROP) (140, 141). The most 
extensively studied poly(ester) polymers are polylactide, polyglycolide, poly(lactide acid-co-
glycolide acid), poly(ε-caprolactone) and lastly poly(ethylene glycol) (141). See table 2 for 
structures. Most poly(esters), especially polyglycolide and polylactide, were originally 
developed to be used as dissolvable sutures, but researchers later discovered that these 
polymers can be used to develop drug-delivery vehicle (142). 
 
The first biodegradable poly(ester) synthesised was polyglycolide (142, 143). Polyglycolide, 
also referred to as poly(glycolic acid) (PGA), is not suitable for a slow-release system due to 
fast degradation and thus is often copolymerized with polylactide and caprolactone (144). 
Under biological conditions, polyglycolide undergoes bulk degradation and produces acetic 
acid as a by-product. The acetic acid is incorporated into biological pathways, thus making it 
safe to be used in biomedical products (145). 
 
Polylactide, also referred to as poly(lactic acid) (PLA), occurs naturally as enantiomeric poly(L- 
lactic acid) and was first described by Carothers in 1932. Carothers produced low molecular 
weight PLA by heating lactic acid under vacuum and removing the condensed water. Later, 
high molecular weight PLA was produced by breaking the lactone ring (143). Polylactide has 
numerous uses in the medical industry, namely as dissolvable sutures, internal fixation devices 
used to support bone fractures and as drug-delivery vehicles (142, 145). 
 
Poly(lactic acid-co-glycolic acid) (PLGA) is a copolymer of polylactide and polyglycolide. A wide 
variety of PLGA forms is commercially available, and they are classified according to the ratios 
of PLA and PGA used (146). This ratio can be used to change the physio-chemical properties 
of PLGA nanoparticles and a rule of thumb, the higher the concentration of PGA the faster the 
copolymer degrades and more hydrophilic the co-polymer (147). The success of PLGA as a 
drug-delivery vehicle is due to the biodegradability of this copolymer. In water, PLGA 
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undergoes hydrolysis of the ester bond and forms two by-products, namely glycolic acid and 
lactic acid. Both these monomers are incorporated into the Krebs cycle, a metabolic pathway 
present in all higher organisms, thus lowering the systemic toxicity of PLGA (148, 149). Both 
the FDA and European Medicine Agency have approved PLGA for use in drug-delivery systems 
in humans and has given PLGA generally regarded as safe (GRAS) status. 
 
Poly(ε-caprolactone) (PCL) is a biodegradable nontoxic polymer produced by ROP of 
caprolactone and was first described by Van Natta and co-authors in 1934 (92, 150, 151). Once 
again, the hydrolysis of PCL forms a by-product, 6-hydroxycaproic acid, that is utilized in the 
Krebs cycle. Due to the slow degradation (even slower than PLA) and high protein permeability 
of PCL, it is mainly used as a delivery vehicle for vaccines. Furthermore, PCL does not create an 
acidic environment during degradation and can thus be used to encapsulate pH-sensitive 
drugs (150). 
 
Poly(ethylene glycol) (PEG) is rarely used alone and is well-known for its use in conjunction 
with other polymers. The hydrophilic nature of PEG reduces aggregation and association with 
nontargeted organelles in the body, thus extending the circulation lifetime of PEGylated 
proteins and nanoparticles in biological environments. Another advantage of PEG is the ease 
of which functional groups can be added to the chain-end of PEG, thus making modification 
quick and simple (141). 
Poly(ortho esters) 
 
 
Poly(ortho esters) (POE) are biodegradable polymers that only release the encapsulated drug 
once hydrolysis of the polymer chains has started. This prevents diffusion of the drug out of 
the nanoparticle device. POE was first described by Choi and Heller in the late 1970s (70, 152–
155). Four different POE families have been developed, POE I at the Alza corporation and the 
other three, POE II, POE III and POE IV, at the Stanford Research Institute, also referred to as 
SRI International (153). 
 
POE I development has stopped due to its autocatalytic nature and low glass transition 
temperature, although it was used in the past to treat burn wounds (156), deliver naltrexone 
(157), a narcotic antagonist and contraceptive steroids (158). Another disadvantage of POE I 
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is its complex and time-consuming synthesis procedure. POE I is synthesised by the 
transesterification of diethoxytetrahydrofuron with diols at high temperatures and under 
vacuum (159). Due to the limitations and complex synthesis of POE I, and desire to develop 
their own POE, SRI International invested in the development of improved families of POE 
(155). 
 
The first POE developed by SRI International was POE II, a unique polymer that forms dense 
crosslinked matrices that biodegrade to small water-soluble molecules (153). This POE is 
synthesised by simply dissolving the two constituents, diol and diketen acetal 3,9- diethylidene 
2,4,8,10-tetraoxaspiro[5.5]undecane, in a polymer solvent and adding an acidic catalyst (155). 
Thus, it is clear that POE II synthesis is a lot less complicated compared to POE I synthesis, and 
the thermal properties of POE II can also easily be adjusted by using diols with different chain 
flexibilities. Furthermore, unlike POE I, POE II does not have an autocatalytic nature since 
neutral products are initially formed during hydrolysis (70, 154). The hydrophobic nature of 
POE II contributes to its stability in physiological environments, since water can’t easily reach 
the water-labile ester links in the polymer backbone. Furthermore, release can be controlled 
by altering the pH of the polymer-water-interface since the majority of the polymer backbone 
links are acid-labile (153). 
 
The next POE developed by SRI international was the semi-solid polymer PEO III. This polymer 
has a flexible backbone and is in a semi-solid state at room temperature. Due to this property, 
drugs are easily encapsulated into POE III nanoparticles. The major downfall of this polymer is 
its complex and time-consuming synthesis procedure. Furthermore, it is near to impossible to 
produce constant polymers with similar molecular weights. Thus, although POE III showed 
promise to be used as a controlled drug-delivery system, development was stopped soon after 
its initial discovery (153). 
 
POE IV was developed by SRI International and first described by Ng and co-authors in 1997 
(153). POE IV, a modified form of POE II, consists of three parts, a lactic or glycolic acid, a diol 
and a diketene acetal (160). By adding an acid moiety (lactic acid or glycolic acid) in the 
backbone of the polymer, Ng and co-workers could ensure hydrolysis of the polymer without 
lowering the pH of the polymer-water interface (153, 154). This is due to the initial hydrolysis 
Stellenbosch University  https://scholar.sun.ac.za
31  
of the water-labile ester bond in the acid moiety that produces a polymer with a carboxylic 
acid end. This acidic polymer is then responsible for the acid hydrolysis of the rest of the 
polymer backbone (161). A major advantage of this polymer is the ability to control the release 
rate by adding or removing the latent acid groups are present in the polymer backbone. In 
other words, the less latent acid groups present, the more slowly the nanoparticle will be 
eroded and the encapsulated drug released (154, 160). 
 
Today, POE nanoparticles are studied extensively to be used as controlled drug-delivery 
devices and numerous articles have been published on the use of POE nanoparticles to control 
post-surgery pain (154), to treat periodontal diseases (162), to use in ocular applications (154) 
and to use as a delivery mechanism for DNA-based vaccines (163). 
 
Poly(anhydrides) 
 
 
Poly(anhydrides) have a long and extensive history and were first synthesised by Bucher and 
Slade in 1909 when they heated isophthalic acid and terephthalic acid with acetic anhydride 
(164). Poly(anhydrides) consist of a hydrophobic polymer backbone with anhydride linkages 
(table 1) and were originally developed to be used in the textile industry but were deemed 
unsuitable for textile applications due to hydrolytic instability (164). 
 
The medical potential of polyanhydrides was only discovered in 1980 by Rosen and co- 
workers (165), who used poly[bis(p-carboxyphenoxy) methane as a poly(anhydride) polymer 
due to its hydrophobicity and toxicology (165, 166). Various techniques are used for the 
synthesis of poly(anhydrides), including melt condensation, ROP, interfacial condensation, 
dehydrochlorination and dehydrative coupling, and depending on the polymer, a specific 
method will be used (167). For example, melt condensation is used for monomers stable at 
high temperatures, while ROP is used to synthesise poly(adipic anhydride) polymers. The 
dehydrative coupling method is used to convert dicarboxylic acid to a poly(anhydride) and the 
major disadvantage of this technique is the presence of the polymerization by-products in the 
final product (168). 
Since the initial discovery of the potential to use polyanhydrides as controlled drug-delivery 
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systems, hundreds of poly(anhydride) structures have been described by various researchers. 
These polymers are grouped into one of ten different classes depending on their structure. 
Therapeutic agents are encapsulated either by compression-molding or microencapsulation 
(141). The FDA have approved two poly(anhydride) drug delivery devices, namely Gliadel® 
(166), used to treat brain tumours, and SeptacinTM (169), used to treat osteomyelitis (Table 2). 
 
Poly(amides) 
 
 
Poly(amides) (PA) are semi-crystalline polymers, consisting of monomers linked with an amide 
(-CONH-) bond (170). Poly(amino acids) are poly(amides) that show the most potential to be 
used for colloidal drug-delivery devices (141). Poly(amino acids) (PAA) are polymers consisting 
of repeating units of a single natural occurring amino acid (the monomer) linked with an amide 
bond (171). The physical and biochemical properties of PAA are easily adjusted by adding 
various moieties to the side chains of the amino acids. Since PAA are enzymatically degraded 
by proteinases, their release rate can be adjusted by modifying the amino acid side chains. 
Biodegradation of PAA produces nontoxic naturally-occurring metabolites that are 
incorporated into its metabolic pathways. The complex synthesis procedure of building PAA is 
their biggest downfall (171). 
 
Polyphosphazenes 
 
 
Polymers containing phosphorus atoms are referred to as polyphosphazenes (PPH). These 
polymers are inorganic-organic hybrids consisting of nitrogen molecules, phosphorus 
molecules and an organic of organometallic side chain (R). The nitrogen and phosphorus 
atoms are linked with single or double bonds while the R group is bound to the phosphorus 
atom (Table 2; 172, 173). The first PPH was synthesised by Stokes in 1897 (174) by ROP of 
hexachorocyclotriphosphazene. The resulting polymer was unstable, insoluble and 
susceptible to hydrolytic cleavage, degrading to phosphates, hydrochloric acid and ammonia. 
These characteristics rendered this polymer unsuitable for use as a controlled drug delivery 
compound (172, 175, 176). 
 
The first useable PPH, poly(dichlorophosphazene) was synthesised by Allcock and Kugel in 
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1965 (177) and in 1966 Allcock reported on the first hydrolytically stable phosphate containing 
polymer with a high-molecular weight (178). This PPH, poly(organophosphazene), was 
synthesised by replacing the chlorine atoms of poly(dichlorophosphazene) with organic or 
organometallic nucleophiles. Modern PPH polymers are synthesised by living cationic 
polymerization, a form of chain polymerization from which chain termination and chain 
transfer is absent, of phosphoranimines, a method designed by Allcock and co-workers in 
1999 (178). This technique allows the synthesis of polymers with a controlled molecular 
weight and narrow polydispersity at room temperature. A unique property of PPH is that these 
polymers undergo bulk and surface erosion and the erosion rate of PPH can be adjusted by 
using different organic or organometallic side chains (175). 
 
During PPH degradation the following nontoxic by-products are formed, ammonia, phosphoric 
acid and an organic or organometallic moiety, depending on the side chain. The unique 
characteristic, backbone flexibility, contributes to the biomedical potential of PPH (175). PPH 
has been used for a variety of biomedical applications including as supporting structures for 
bone and soft tissue regeneration (172) and in 2000 Calceti and co-authors. reported the use 
of PPH microspheres for the controlled delivery of insulin (179). 
Table 1: The structures of synthetic polymers commonly used for controlled drug delivery 
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Table 1 continued 
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Nanoparticle synthesis 
 
 
From the section above, it is clear that nanoparticles are synthesized from various different 
polymers and each polymer has some advantages and disadvantages. Nanoparticles 
fabrication methods are divided into two groups: bottom-up methods and top-down methods 
(183). In bottom-up methods, nanoparticle and polymer formation is done simultaneously, 
while top-down methods use preformed polymers to encapsulate drugs (184, 185). Various 
top-down methods used to encapsulate drugs in a nanoparticle core or shell-like polymer 
matrix will be discussed below. Similar to the various polymers, each technique comes with a 
list of advantages and disadvantages. Figure 4 provides a short overview of all the techniques 
used to synthesise nanoparticles. 
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Fig. 4: General methods used for the synthesis of polymer nanoparticles, including a brief description 
of each method. 
 
 
Emulsification-solvent evaporation technique 
 
 
The most common and oldest technique used for the production of polymer nanoparticles are 
the emulsification-solvent evaporation technique, a two-step process (186–190). The polymer 
and therapeutic drug are emulsified in an aqueous solution followed by evaporation of an 
organic solvent (184). The evaporation of the organic solvent induces the precipitation of the 
polymer and drug as nanoparticles. Surfactants or stabilisers are added to prevent aggregation 
of the nanoparticles during formation (191) and sonication or homogenization are often used 
to ensure formation of nanosized particles (92). 
 
The polymer and therapeutically active drug are dissolved in an organic solvent, 
dichloromethane is often used for PLGA nanoparticles. The polymer solution is, subsequently, 
emulsified in an aqueous solution, often water, containing a surfactant (PVA, methylcellulose 
and gelatin) as a stabiliser (192) and nanosized emulsions are induced by sonication. The 
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organic solvent is allowed to evaporate, inducing the formation of nanoparticles. 
Nanoparticles are collected by centrifugation and freeze-frying (186, 193). Unfortunately, this 
method can only be used to encapsulate hydrophobic drugs, thus a new method had to be 
developed, the double emulsification-solvent evaporation method. 
 
Double emulsification-solvent evaporation 
 
 
The double emulsification-solvent evaporation method, developed by Vracken and co- 
workers in 1970 (194), is a modified version of the emulsification-solvent evaporation method 
used to encapsulate hydrophilic drugs (156). The method is divided into three steps, formation 
of a water-in-oil (w/o) emulsion, formation of a water-in-oil-in-water (w/o/w) emulsion and 
lastly evaporation of the organic solvent. For the formation of the w/o emulsion, the 
hydrophilic drug is dissolved in an aqueous solution, often water, and the polymer dissolved 
separately in an organic solvent containing a surfactant. The organic solvent, containing the 
surfactant, and polymer are sonicated to induce formation of nanosized oil droplets. The 
w/o/w emulsion is produced by mixing and sonicating the aqueous and organic solutions. The 
mixing step is extremely important and should be controlled to prevent excessive diffusion of 
the drug into the external aqueous phase. Once the w/o/w emulsions have formed the organic 
solvent is allowed the evaporate and the nanoparticles are collected by centrifugation and 
freeze drying (195–198). 
 
The disadvantages associated with this method are the size and the low encapsulation 
efficiency of nanoparticles. Song and co-workers (199) proposed using a second strong shear 
force during formation of the w/o/w emulsion to decrease the size of the nanoparticles, but 
it was also noticed that as the shear force increases the drug encapsulation efficiency 
decreases (185). Increasing the polymer concentration and using polymers with high 
molecular weight can improved the drug encapsulation efficiency. 
 
Emulsification-diffusion 
 
 
The emulsification-solvent-diffusion (ESD) method relies on the diffusion of an organic solvent 
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into an external aqueous solution for particle formation (191). The ESD method was first 
proposed by Niwa and co-workers in 1993 for the encapsulation of water soluble and insoluble 
drugs in PLGA (200, 201). The original method proposed by Niwa and co-workers used a 
mixture of acetone and dichloromethane or chloroform as the water-miscible solvent, but due 
to severe aggregation when the method was upscaled for industrial production, the method 
had to be modified. Murakami and co-workers proposed a modified version of the ESD 
method in 1999 (202). 
 
The modified method, described below, uses two nontoxic organic solvents to dissolve the 
polymer and drug and form the organic phase. This eliminates the need to evaporate the 
organic solvent. The polymer and drug are dissolved in a combination of two water miscible 
organic solvents, such as methanol/acetone or ethanol/acetone, forming the organic phase. 
The organic phase is emulsified in the aqueous phase consisting of water and a suitable 
surfactant, such as nonionic PVA or anionic sodium dodecyl sulphate (SDS). Nanoparticle 
formation is induced by diffusion of the organic solvent into the external aqueous phase (185, 
202). 
 
Advantages associated with the modified ESD method are, absence of toxic organic solvents, 
low energy consumption (no need for sonication of homogenization), high encapsulation 
efficiency, low batch-to-batch variability and evaporation is avoided. Disadvantages 
associated with the modified ESD method are requires large amounts of water, timely process 
(takes a while for the emulsification to form) and can only be used to encapsulate hydrophobic 
drugs (184, 185, 202). 
 
Salting out process 
 
 
The salting-out process is a modified version of the ESD method (184). The salting-out process 
was first patented by Bindschaedler co-authors in 1988 (203), and later modified by Allémann 
co-workers to eliminate the use of surfactants (204). 
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The salting-out process consists of three steps, i.e. preparing the organic and aqueous phases, 
emulsification and precipitation. The polymer and drug are dissolved in an organic solvent, 
such as acetone, to create the organic phase. The aqueous phase consisting of water, a water 
soluble polymer and a high concentration of a salting out agent, often magnesium chloride 
hexahydrate or magnesium acetate tetrahydrate (185, 204, 205). Under magnetic stirring, the 
organic phase is emulsified in the aqueous phase, creating the o/w emulsion. The high salt 
concentration prevents the diffusion of the organic solvent into the aqueous phase by altering 
the miscibility of water. Nanoparticles are precipitated by adding an excess amount of water, 
subsequently diluting the salting out agent and allowing the organic solvent to diffuse into the 
aqueous phase, resulting in nanosized emulsions. The salting out agent and any remaining 
solvents are removed by cross flow filtration and centrifugation (184, 185, 204–207) . 
 
Unfortunately, although this method is free of nontoxic solvents and can be used to 
encapsulate sensitive hydrophobic peptides, upscaling for industrial use is not an option due 
to a low nanoparticle yield (191). 
 
Nanoprecipitation 
 
 
Nanoprecipitation, also known as interfacial deposition of solvent displacement, was 
developed by Fessi and co-workers in 1989 (208). The method is based on the interfacial 
deposition of a polymer due to the displacement of a semi-polar solvent (miscible in water) 
from a hydrophobic solution (the oil phase) (191, 209, 210). Nanoprecipitation is widely used 
for the development of poly(ester) controlled drug release systems, even though it is only used 
for the encapsulation of hydrophobic drugs (209, 211, 212). 
 
Nanoparticles are produced by dissolving the polymer in an organic solvent, miscible with 
water, and adding the organic phase drop wise to the aqueous solution. The aqueous solution 
consists of a water miscible solvent, in which the polymer cannot dissolve, and a surfactant. 
As the organic solvent drops into the aqueous solvent, nanoparticles are formed by rapid 
solvent diffusion. The organic solvent is removed under reduced pressure (184, 185, 205, 209, 
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211, 212). Nanoparticles form due to the difference in surface tension of the organic/oil 
solvent and the aqueous solvent. Compared to the organic solvent the surface tension of the 
aqueous solvent is higher, causing interfacial turbulence and thermal inequalities. This leads 
to the formation of vortices on the surface of the solvents and the diffusion of the organic 
solvent out of regions with low tension. The diffusion causes the precipitation of the polymer 
and subsequently the formation of nanoparticles (213, 214). 
 
Nanoprecipitation is known for producing small nanoparticles with a narrow size distribution, 
in the absence of toxic solvents and a high energy input. High reproducibility and low batch 
variation renders this method ideal for industrial production of nanoparticles encapsulating 
hydrophobic drugs. A modified nanoprecipitation method for encapsulating hydrophilic drugs 
was recently developed by Bilati and co-workers (185, 215–217). Unfortunately, evaporation 
of the organic solvent is a time-consuming process rendering this process less attractive for 
industrial production. 
 
Phase inversion temperature 
 
 
The phase inversion temperature (PIT) method is a low-energy emulsification method that is 
solvent-free (218, 219). The method was developed by Shinoda and Saito in 1968 (220) and is 
based on the phase transition of an emulsion due to a change in the curvature of a nonionic 
surfactant, brought on by a change in temperature (221). Phase transition is possible due to 
the unique curvature properties of nonionic surfactants. Nonionic surfactants have oxygen-
containing hydrophilic groups covalently bound to the hydrophobic parent structure and the 
oxygen bonds are water soluble due to the hydrogen bonds (222). At low temperatures, 
nonionic surfactants have a positive curvature and are hydrophilic, while the nonionic 
surfactants are hydrophobic at high temperatures due to a negative curvature. At the PIT of 
the nonionic surfactant (curvature of zero), nanoemulsions appear and extremely small 
nanoparticles (50 – 120 nm) are produced due to the low interfacial tension (221). To 
encapsulate drugs with the PIT method an o/w emulsion is formed by dissolving the drug and 
nonionic surfactant in an aqueous solvent and subsequently mixing the aqueous and organic 
solvents. The o/w emulsions are then heated (to the PIT), resulting in inversion (w/o) of the 
emulsions. This is followed by rapid cooling of the solution and the formation of stable 
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nanoparticles (218,221, 223, 224). 
 
Electrospraying/dropping method 
 
 
Electrospraying is a one-step synthesis technique based on electrospinning, a technique used 
to produce nanofibers (225). Electrospraying and electrospinning are based on the ability of 
an electrical current to deform the surface of a liquid. The principle was first established by 
Lord Rayleigh in 1882 (226) and later improved on by Zeleny in 1917 (227) and Sir Taylor in 
1964 (228). When comparing electrospraying to more traditional emulsification methods, a 
few advantages can be identified. The advantages include the synthesis of nanosized particles 
with a narrow size distribution, the absence of toxic organic solvents and solvent evaporation 
and a high encapsulation efficiency of hydrophobic and hydrophilic drugs at ambient 
conditions. The single syringe system can be adapted to a multiple syringe system for 
industrial production purposes (229–233). 
 
An electrospraying setup consists of three components a power supply, syringe pump and a 
grounded collector (230). The polymer and drug are dissolved in a water miscible organic 
solvent and placed in the pump syringe. The high voltage power supply is connected to the tip 
of the syringe and the particles are collected at the grounded collector. Nanoparticles can be 
collected in one of two methods, on a grounded plate or in a grounded solution (231). The 
nanoparticles form when the polymer solution enters the electrical field, elongating the 
meniscus to form a Taylor cone-jet (a conical shaped meniscus). Once the cohesion forces in 
the drop overcome the coulomb force, created by the electrical current, the surface tension 
is released and nanodroplets are formed. As the droplets migrate to the grounded collector, 
the solvent evaporates, producing nanosized particles (225, 229–234). 
 
The size and shape of the particles depend on various factors, including the polymer 
concentration, distance from the grounded collector and voltage applied (229, 231, 234). By 
adding a surfactant or protective colloid to the electrospraying solution, aggregation of the 
particles can be prevented. This is especially useful when the system is upscaled and a multi- 
syringe system is being used (191). 
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Supercritical fluid technology 
 
 
The existence of supercritical fluids (SCF) was first observed by Cagniard de la Tour in 
1822 (235) and the enhanced solubility of solids in SCFs was reported by Hannay and Hogarth 
in 1879 (236). A SCF is defined as a monophasic fluid above its critical temperature and 
pressure, with properties of both liquids and gaseous substances (191, 237). Supercritical fluid 
technology (SFT) is a term used to refer to all techniques that use SCFs (238). Due to the non- 
toxic, “green” (non-polluting) and economical properties of SCFs, the technology has attracted 
the interest of the pharmaceutical industry for the production of nanosized drug-delivery 
devices (239). SCFs can be used as solvents, anti-solvents and plasticisers for the synthesis, 
purification and modification of synthetic polymers. In contrast to conventional techniques SFT 
is used to “grow” the particle to the appropriate size, instead of reducing the size of a larger 
particle formed by emulsification (238). The most commonly used SCF is supercritical CO2 (SC-
CO2), due to FDA approval for use in pharmaceutical processes, low toxicity, low cost, low 
density and mild supercritical conditions (237, 239, 240). 
 
Various techniques have been developed for the production of nanoparticles using SFT, and 
these techniques can be categorized based on whether the SCF is used as a solute, solvent or 
anti-solvent (239). Particle formation from gas-saturated solutions (PGSS), rapid expansion of 
supercritical solutions (RESS), supercritical anti-solvent (SAS), gaseous anti-solvent (GAS), 
aerosol solvent extraction system (ASES) and depressurization of an expanded liquid organic 
solution (DELOS) are techniques discussed in this review. 
 
For the PGSS compressed SC-CO2, the SCF, acts as the solute and is dissolved in a molten 
polymer. The solution is allowed to expand across a nozzle, allowing the SCF to evaporate and 
a fine dry powder of nanoparticles to form (238, 239). In the RESS technique, the SCF acts as 
a solvent. The main drawback of this method is the poor solubility of the polymers and 
pharmaceutical compounds in SCFs. Nanoparticles are formed when the saturated SCF is 
depressurized in a heated nozzle connected to a low-pressure chamber. The depressurization 
leads to rapid nucleation of the polymer/drug substrate, forming nanoparticles (238, 239). In 
principle the SAS and GAS techniques are similar. These two methods are used for polymers and 
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drugs with a poor solubility in SCFs, thus the SCF acts as an anti-solvent. In the SAS method, the 
polymer and drug are dissolved in an organic solvent. The organic solvent is charged with the 
SCF in a precipitation vessel. The pressure of the vessel is increased, allowing the SCF to enter 
a liquid phase and to saturate the organic solvent, leading to precipitation (116). In the GAS 
process, the organic solvent is saturated with a gas. Reducing the solubility of the solvent, 
leading to particle precipitation (238).  
 
The ASES technique is closely related to the SAS and GAS techniques. The polymer and drug 
are dissolved in an organic solvent, but in contrast to the SAS technique, the organic phase is 
sprayed through an atomization nozzle into compressed SC-CO2. This is followed by the 
dissolution of the SCF into the liquid drops, formed by the atomization nozzle, reducing the 
solubility of the liquid solvent, causing supersaturation of the liquid and the formation of 
nanoparticles (238, 241). The main downfall of the ASES procedure is its low drug-loading 
efficiency compared to the other techniques (239). The DELOS method uses SFCs as co-
solvents. The method is preferred over SAS since it can be used for heat sensitive drugs, uses 
small amounts of SC-CO2 and is upscaled with ease (239).  
 
The DELOS process uses compressed SCFs, miscible with the organic solvents at a given 
temperature and pressure, as a co-solvent. The compressed SCF causes homogenous 
supercooling of the solution, leading to particle precipitation (242). 
 
Advanced methods 
 
 
A central problem of the above mentioned techniques is the inability to control the 
homogenous mixing of solvents and the subsequent controlling of the size distribution and 
physiochemical properties of nanoparticles (210). This led to the development of two 
advanced techniques for the production of nanoparticles, namely incorporation of 
microfluidic devices and PRINT (183, 191). 
 
The use of microfluidic devices for the synthesis of nanoparticles was first reported by 
Kawakatsu and co-authors in 2000 (243, 244). Nanoparticles formed in microfluidic devices 
are fabricated by a competition between the interfacial force and shear stress, imposed by 
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the continuous flow of the organic and aqueous solvents (191). Kawakatsu and co-authors 
also reported that the geometry of the microfluidic device can greatly impact the size 
distribution of the particles (243, 244). Nano-emulsions are solidified by ionic crosslinking, 
solvent evaporation, solvent diffusion, radical polymerization or by condensation (191). 
 
The advantages of this method are the ease of controlling nanoparticles size by manipulating 
the solution flow, the high encapsulation efficiency (more than 90%), the portability of the 
device for in situ production and low operating costs. This process is used for industrial scale 
production by modifying the microfluidic device to consist out of multiple channels (191). 
 
Particle Replication In Non-wetting Template (PRINT), was developed by Rolland and co-
workers in 2005 (245). It is a roll-to-roll, high resolution, continuous technique inspired by 
microelectronics and lithography (87, 191). PRINT is used to produce nanoparticles with a 
narrow size and shape distribution by using a perfluoropolyether mold with a defined pattern 
(87). Perfluoropolyether is a non-wetting, gas-permeable, nontoxic, inert polymer that is 
resistant to swelling in the presence of most organic acids and has a low surface energy (87, 
183, 246). These characteristics ensure the production of monodispersed nanosized particles 
that are easily removed from the mold (247). The loading and encapsulation efficiency of the 
PRINT technique is extremely high when compared to the other top-down techniques (>90%) 
(191) and is used to encapsulate hydrophobic and hydrophilic drugs on an industrial scale at 
low cost (247). Due to the gas permeability of perfluoropolyether, the polymer can be 
dissolved in volatile organic acids, removed by evaporation during the hardening step (191). 
PRINT has been used to create polymeric nanoparticles from various materials including PLGA, 
PLA, PEG and poly(silyl ether) (183). 
 
Nanoparticles are produced by dissolving the polymer and drug in an organic solvent and 
pouring the solution onto the mold. A roller is used to evenly disperse the solution and due to 
the low surface energy, the mold prevents overflow of the polymer solution to non-cavity 
areas. Individual nanoparticles are subsequently formed. Once the particles have cured in the 
mold and the organic solvent has evaporated, the particles are removed from the mold and 
collected with film-based techniques (87, 246, 247) 
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Current applications of nanoparticles 
 
 
The majority of controlled drug delivery devices (nanoparticles) approved by the FDA for 
medical use are cancer-related (Table 2), which is due to the high toxicity of chemotherapy 
agents. Thus it is only natural that the first nanoparticle approved by the FDA was a 
chemotherapeutic agent, liposome encapsulated doxorubicin, Doxil® (approved 1995), (81). 
Although Adagen® (approved 1990) is classified as a nanoparticle, in truth it is only a PEGylated 
form of the adenosine deaminase enzyme to improve the circulation of the enzyme (248). The 
approval of Doxil® opened the door for numerous other nanoparticle formulations to be 
developed for the medical industry. 
 
Doxil® approval was followed by the approval of Abelcet® in 1995, the first encapsulated 
antimicrobial agent (249). Abelcet® proved that nanoparticles can be used to reduce the 
toxicity of antimicrobials, and can be used to circumvent antimicrobial resistance. This led to 
a boom in the nanomedicine industry, and at least 45 nanoparticle formulations have been 
approved for various illnesses in the last 20 decades. In 1996, the first magnetic nanoparticle 
used as a liver-specific imaging agent, Feridex® (Endorem®), was approved by the FDA (250– 
252). In 2001 the first nanoparticle formulation, PegIntron®, for the treatment of a viral 
disease, hepatitis C, was approved by the FDA (253), followed by the approval of Pegasys®. 
Pegasys® is a PEGylated form of interferon alpha 2a, for treating hepatitis B and hepatitis C 
infections (254). The first nanocrystal approved by the FDA was Rapamune®, an 
immunosuppressant to prevent organ rejection (255). Megace EC was the first nanoparticle 
approved, for the treatment of mental disorders (255) and was followed by the approval of 
Ritalin LA® (256) and Focalin® (257). A number of nanoparticle formulations used as bone 
substitutes have been approved by the FDA, including Vitoss® (258), Ostim® (259), OsSatura® 
(260, 261), NanOss (262) and EquivanBone (263, 264). 
 
It is thus clear that nanotechnology have made a great impact on the pharmaceutical industry 
in the last 20 decades and has become a big industry with a net worth of $26 billion in 2014 
(265). It is believed that as material science grows, the nanotechnology industry will grow even 
more and it is expected to have a net worth of $64.2 billion by 2019.
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Table 2: A list of all the nanoparticle formulations that have been approved by the FDA up to 
2016 
Type of 
Particle 
Name 
Production 
material 
Treatments 
Year 
approved 
Ref. 
Sy
nt
he
tic
 P
ol
ym
er
 N
an
op
ar
tic
le
 
Adagen®/ 
pegademase 
bovine (Sigma-Tau 
Pharmaceuticals)  
PEGylated 
adenosine 
deaminase 
enzyme 
Severe combines 
immunodeficiency 
disease (SCID) 
1990 (266) 
SeptacinTM 
Gentamicin 
encapsulated in 
polyanhydride 
 
Osetomyelitis 
2002 (169) 
Cimzia® / 
Certolizumab pegol 
(UCB) 
PEGylated 
antibody 
fragments 
Crohn’s disease 2008 
(231, 
232) 
 
 
Rheumatoid 
arthritis 
2009 
Psoriatic arthritis 2013 
Ankylosing 
Spondylitis 
2013 
Copaxone®/ 
Glatopa (Teva) 
Copolymer of 
L-Glutamate, L-
alanine, 
L-lysine and  
L-tyrosine 
Multiple Sclerosis 1996 
(268) 
 
Eligard® (Tolmar) 
Leuprolide 
acetate coupled 
to poly(DL-
Lactide-co-
glycolide) 
Prostate cancer 2002 
(269, 
270) 
Macugen®/ 
Pegaptanib 
(Bausch & Lomb)  
PEGylated anti-
vascular  
Macular 
degeneration, 
neovacular age-
related 
2004 (271) 
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Table 2 continued 
 
Type of 
Particle 
 
Name 
Production 
material 
 
Treatments 
Year 
approved 
 
Ref. 
 
Mircera®/Methoxy 
polyethylene glycol- 
epoetin beta 
(Hoffman-La Roche) 
 
Chemically 
synthesized ESA 
Anaemia associated 
with chronic kidney 
disease 
 
 
2007 
 
 
(272) 
 
 
Neulasta®/ 
pegfilgrastim(Amgen) 
 
PEGylated GCSF 
protein 
Neutropenia, 
Chemothera
py 
induced 
 
2002 
 
(273, 
274) 
  Pegasys®(genentech) 
PEGylated IFN 
alpha-2a protein 
Hepatitis B, 
Hepatitis C 
 
2002 
 
(254) 
  PegIntron®(Merck) 
PEGylated IFN 
alpha-2b protein 
 
Hepatitis C 
 
2001 
 
(253) 
 
Sy
nt
he
tic
 P
ol
ym
er
 N
an
op
ar
tic
le
 Renagel®[sevelamer 
hydrochloride]/ 
Renagel®[sevelamer 
carbonate] (Sanofi) 
 
Poly (allylamine 
hydrochloride) 
 
Chronic 
kidney 
disease 
 
 
2000 
 
 
(275) 
 
Somavert®/ 
Pegvisomant (Pfizer) 
PEGylated HGH 
receptor 
antagonist 
 
Acromegaly 
 
2003 
 
(276) 
Oncaspar®/ 
pegaspargase 
(Enzon 
Pharmaceuticals) 
Polymer-protein 
conjugate 
(PEGylated L- 
asparaginase) 
 
Acute 
lymphoblast
ic leukaemia 
  
 1994 (277) 
 
 
Krystexxa®/ 
pegloticase 
(Horizon) 
Polymer-protein 
conjugate 
(PEGylated 
porcine-like 
uricase) 
 
 
 
Chronic gout 
 
 
 
2010 
 
 
 
(278) 
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Table 2 continued 
 
Type of 
Particle 
Name 
Production 
material 
Treatments 
Year 
Approved 
Ref. 
Sy
nt
he
tic
 P
ol
ym
er
 N
an
op
ar
tic
le
 
Plegridy®(Biogen) 
Polymer-
protein 
conjugate 
(PEGylated IFN 
beta-1a) 
Multiple Sclerosis 2014 (279) 
Adynovate (Baxalta) 
Polymer-
protein 
conjugate 
(PEGylated 
factor VIII) 
Haemophilia 2015 (280) 
Gliadel® (MGI 
Pharma) 
Carmustine 
encapsulated in 
polyanhydride 
Recurrent glioma 1996 (281) 
Lip
os
om
e 
Na
no
pa
rt
icl
e 
DaunoXome® 
(Galen) 
Liposome 
Daunorubicin 
Karposi’s 
Sarcoma 
1996 
(282–
284) 
DepoCyt©  
(Sigma-TAU) 
Liposomal 
Cytarabine 
Lympomatous 
meningitis 
1996 
(284, 
285) 
Marqibo® (Onco 
TCS) 
Liposomal 
Vincristine 
Acute 
Lymphoblastic 
Leukemia 
2012 
(286, 
287) 
Onivyde® 
(Merrimack) 
Liposomal 
Irinotecan 
Pancreatic cancer 2015 (288) 
AmBisome®  
(Gilead Sciences) 
Liposomal 
Amphotericin B 
Fungal/Protozoal 
infection 
1997 
(284, 
289) 
Visudyne® 
(Bausch and Lomb) 
Liposomal 
Verteporfin 
Macular 
degeneration, 
myopia, ocular 
histoplasmosis 
2000 
(284, 
290) 
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Table 2 continued 
 
Type of 
Particle 
Name 
Production 
material 
Treatments 
Year 
Approved 
Ref. 
Lip
os
om
e 
Na
no
pa
rt
icl
e 
DepoDur®  
(Pacira 
pharmaceuticals) 
Liposomal 
Morphine Sulphate 
Analgesia (Post-
operative) 
2004 (291) 
Doxil®/CaelyxTM 
(Janssen) 
Liposomal 
doxorubicin 
Karposi’s sarcoma  1995 (81, 
284, 
292) 
Ovarian cancer 2005 
multiple myeloma 2008 
Abelcet®(Sigma-Tau) 
Liposomal 
Amphotericine B 
lipid complex 
Fungal infections 1995 (249) 
Curosurf®/Poractant 
alpha  
(Chiesei farmaceutici) 
Liposome-proteins 
SP-B and SP-C 
Pulmonary 
surfactant for 
respiratory Distress 
syndrome 
1999 (293) 
M
ice
lla
r 
Na
no
pa
rt
icl
  Estrasorb
TM 
(Novavax) 
Micellar Estradiol 
Menopausel 
therapy 
2003 
(294, 
295) 
Pr
ot
ei
n 
na
no
pa
rt
icl
es
 Abraxane®/ABI-007 
(Celgene) 
Albumin-bound 
paclitaxel 
nanoparticles 
Breast cancer 2005 (232, 
296, 
297) 
NSCLC 2012 
Pancreatic cancer 2013 
Ontak® (Eisai Inc) 
Engineered protein 
combining IL-2 and 
diphtheria toxin 
Cutaneous T-Cell 
Lymphoma 1999 
(296) 
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Table 2 continued 
 
Type of 
Particle 
Name 
Production 
material 
Treatments 
Year 
Approved 
Ref. 
Na
no
cr
ys
ta
ls 
Emend®(Merck) Aprepitant Antiemetic 2003 (296) 
Tricor® 
(Lupin Atlantis) 
Fenofibrate Hyperlipidermia 
2004 
(298, 
299) 
Rapamune® (Wyeth 
pharmaceuticals) 
Sirolimus Immuno-
suppressant 
2000 
(255) 
Megace ES® 
(Par pharmaceuticals) 
Megestrol 
acetate 
Anti-anorexic/ 
weight gain 
2001 
(255) 
Avinza® (Ligand 
Pharmaceuticals) 
Morphine 
sulphate 
Severe pain 2002 
(2015) 
(300) 
Focalin XR® 
(Novartis) 
Dexamethyl-
phenidate HCL 
Psychostimulant 
(ADHD 
treatment) 
2005 
(257) 
Ritalin LA® (Novartis) 
Methyphenidate 
HCL 
Psychostimulant 
(ADHD 
treatment) 
2002 
(256) 
Zanaflex® (Acorda) Tizanidine Muscle relaxant 2002 (301) 
Vitoss® (Stryker) 
Calcium 
phosphate 
Bone substitute 
2000 
(258) 
Ostim® 
(Heraseus Kulzer) 
Hydroxyapatite Bone substitute 
2004 
(259) 
OsSatura® (IsoTis 
Orthobiologics) 
Hydroxyapatite 
and Calcium 
phosphate 
Bone substitute 
2003 
(260, 
261) 
 NanOss® (Rti Surgical) Hydroxyapatite Bone substitute 2005 (262) 
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Table 2 continued 
 
Type of 
Particle 
Name 
Production 
material 
Treatments 
Year 
Approved 
Ref. 
Na
no
cr
ys
ta
ls 
EquivaBone® 
(Zimmer Biomet) 
Hydroxyapatite Bone substitute 2009 
(263, 
264) 
Invega® Sustenna® 
(Janssen 
Pharmaceuticals) 
Paliperidone 
Palmitate 
Schizophrenia 2009 
(302, 
303) Schizoaffective 
Disorder 
2014 
Ryanodex® (Eagle 
Pharmaceuticals) 
Dantrolene sodium 
Malignant 
hypothermia 
2014 (304) 
In
or
ga
ni
c /
 m
et
al
lic
 n
an
op
ar
tic
le
s 
Nanotherm® 
(MagForce) 
Iron oxide Glioblastoma 2010 
(250
–
252) 
FerahemeTM / 
Ferumoxytol  
(AMAG 
pharmaceuticals) 
Ferumoxytol SPION 
with polyglucose 
sorbitol 
carboxymethylether 
Anemiairon 
deficiency in 
chronic kidney 
disease 
2009 (305) 
Venofer®  
(Luitpold 
pharmaceuticals) 
Iron sucrose 
Iron deficiency in 
chronic kidney 
disease 
2000 
(306
–
309) 
Ferrlecti®  
(Sanofi Avertis) 
Sodium ferric 
gluconate 
Iron deficiency in 
chronic kidney 
disease 
1999 
(306, 
308, 
309) 
INFeD® (Sanofi 
Avertis) 
Iron dextran (low 
MW) 
Iron deficiency in 
chronic kidney 
disease 
1992 
(306
–
310) 
DexIron® / 
Dexferrum® (Sanofi 
Avertis) 
Iron Dextran (high 
MW) 
Iron deficiency in 
chronic kidney 
disease 
1996 
(307, 
308, 
311) 
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Table 2 continued 
 
Type of 
Particle 
Name 
Production 
material 
Treatments 
Year 
Approved 
Ref. 
In
or
ga
ni
c /
 m
et
al
lic
 
na
no
pa
rt
icl
es
 
Feridex®/Endorem® 
(AMAG 
pharmaceuticals) 
SPION coated 
with dextran 
Liver-specific 
imaging agent 
1996 
(250–
252) 
GastroMARK™/ 
Lumiren™ 
(AMAG 
pharmaceuticals) 
SPION coated 
with dextran 
Gastro-intestinal 
tract imaging 
agent 
2001 
(312, 
313) 
 
 
Mesenchymal stem cells 
 
 
Osteoarthritis (OA) is a bone disorder that occurs in about 22.7 % of the world population 
(314). The only treatment available for severe OA is total joint arthroplasty (TJA) surgery and 
99% of all total hip arthroplasties (THA) are due to arthritis-related pain and functional 
limitations (315). According to a report released by the CDC in February 2015, the amount of 
THA performed more than doubled from the year 2000 to 2010 (316). This is due to the high 
success rate of THA and the ever-aging population of the 21st century. Even though THA is seen 
as one of the most successful operations of the century (317), complications do occur (318–
322). One of the primary reasons for early THA failure is periprosthetic joint infection (PJI) 
(319, 323). 
 
Periprosthetic joint infection (PJI) is defined as an infection of the joint prosthesis and adjacent 
tissue (320). According to the Musculosketal Infection Society (MSIS), PJI can be identified 
when one of the following symptoms is present, a sinus tract (wound tunnel) that makes 
contact with the prosthesis or when pathogens can be isolated from two separate tissue 
samples (318). Staphylococcus aureus biofilm formation is associated with 38% of PJI and is 
extremely difficult to eradicate, since 53% of these strains are methicillin-resistant (319, 322). 
In severe cases PJI, is treated by administrating different combinations of antibiotics 
intravenously for two to six weeks (324). If the infection persists the prosthesis is removed 
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and the joint flushed with antibiotics, followed by a 12-week course of antibiotic treatment 
(319). Once the infection has cleared, a new prosthesis is inserted. 
 
The effect of this direct application of antibiotics on osteoblast cells is largely unknown. 
Osteoblast proliferation and function is traditionally evaluated in vitro using bone-derived 
mesenchymal stem cells (bmMSC). In 2006, the International Society for Cellular Therapy 
Position proposed a three-part criteria for identifying mesenchymal stem cells, (a) the ability 
to adhere to plastic in vitro; (b) the expression (e.g. CD105, CD90 and CD73) and absence (e.g. 
CD45, CD34, CD 19, CD79a, CD14, CD11b and HLA-DR) of a range of cell markers as assessed 
by flow cytometry; and (c) ablity to differentiate into osteoblasts, chondroblasts and 
adipocytes (325). This criteria was proposed for human MSC, but may not apply uniformly to 
all species, since it has been shown that murine MSCs express different cell markers in vitro 
(326). The presence of MSCs in bone marrow was first reported by Cohneim (327, 328) in 
1867. In the 1970s, Friedenstein and co-authors reported the ability of these bone-marrow cells 
to form colonies on plastic in vitro (329), designating the cells as colony forming units. A few 
years later Castro-Malaspina (330) succeeded in isolating these cells from humans and in 1999, 
Pittenger and co-authors (331) reported that bone-marrow derived cells were multipotent and 
could give rise to various mesenchymal cell lineages in vitro. Recently, Jacobs and co-authors 
described a second phenotypically, but functionally distinct population of mesenchymal stem 
cells, isolated from the proximal end of murine femora (pfMSC) (332). These cells were shown 
to have a decreased osteogenic potential and increased sensitivity to the cytotoxic effects of 
glucocorticoids. 
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The increase in antibiotic resistance has shifted the focus towards screening microorganisms 
from less explored niches for novel antimicrobial compounds. In this study, we report on the 
isolation and purification of two xenocoumacin 2–like antibiotics and a novel broad-spectrum 
antimicrobial compound from a strain of Xenorhabdus khoisanae associated with the 
entomopathogenic nematode Steinernema khoisanae. Both antibiotics have a mass-to- 
charge (m/z) ratio of 407, similar to that reported for xenocoumacin 2. The larger antimicrobial 
compound (m/z ratio = 671) has not yet been reported. The three compounds were isolated 
by exposing colonies to XAD-16 beads. The hydrophobic extracts from colonies was further 
purified by HPLC. Fractions collected from three peaks were active against Staphylococcus 
aureus Xen 31 (methicillin-resistant) and Xen 36 (methicillin-sensitive). Further characterisation 
was done by UHPLC-MS (ultra-high-pressure liquid chromatography-tandem mass 
spectrometry) and UV-Spectrum analysis. This is the first report of xenocoumacin-like 
antibiotics and an antimicrobial compound with a m/z ratio of 671 produced by X. khoisanae. 
The antimicrobial compound, named rhabdin, is cytotoxic to mesenchymal stem cells (MSCs), 
but only at levels exceeding 3.5 mg/L. Further characterization by H3-NMR is in progress. 
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INTRODUCTION 
 
 
In the early-to-mid 1900s, more than 20 novel classes of antibiotics were discovered (1, 2), but 
only three novel classes have entered the market since 1962 (3). Microorganisms from unique 
environments, and living in close symbiotic relationship with their hosts, may be a source of 
novel antibiotics or antibiotic-like compounds. The genus Xenorhabdus, classified as a member 
of the family Enterobacteriaceae, lives in close association with nematodes of the genus 
Steinernema, which in turn infects insects from various orders including Lepidoptera, Diptera, 
Orthoptera, Coleoptera and Hymenoptera (4). Once a nematode is infected with 
Xenorhabdus, the bacterial cells produce antimicrobial compounds, including antibiotics and 
bacteriocins to exclude other microorganisms (5). These compounds produced by Xenorhabdus 
are so successful at eradicating other microorganisms that pure cultures are isolated directly 
from infected nematodes. Only a few papers have been published on the antimicrobial 
properties of Xenorhabdus spp. (6–16). 
 
The eradication of biofilm-forming bacteria, especially on prosthetic implants, is extremely 
difficult. Staphylococcus aureus is associated with 38% of prosthetic joint infections (PJIs) (17). 
Of these strains, 53% were methicillin-resistant (17, 18). Other pathogens include coagulase- 
negative staphylococci (19, 20), Escherichia coli and Klebsiella pneumoniae (17). In severe 
cases of PJIs, different combinations of antibiotics have to be administered intravenously for 
2 to 6 weeks (21). Bactericidal antibiotics such as rifamycins, lipiarmycins, quinolones and 
sulfonamides that inhibit the transcription of RNA and protein synthesis, are usually used to 
treat prosthetic PJIs (20, 22). Of these, rifamycins have the best biofilm penetration properties 
(19). However, due to constant single-point mutations in the RNA polymerase gene, 
pathogens treated with rifamycins develop resistance rapidly (19). Rifamycins should thus 
always be used in combination with other antibiotics, such as levofloxacin (a fluoroquinolone). 
Quinolones have a different target site and inhibit the function of DNA gyrase and 
topoisomerase IV, thus DNA replication (23).  
Treatment with an oral rifampicin- fluoroquinolone combination may be as long as 6 months, 
depending on the severity of the infection (21). If the infection persists, the prosthesis needs 
to be removed and the infected joint flushed with antibiotics (referred to as one-step revision 
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surgery). Patients are then usually put on a 12-week antibiotic course. Once the infection has 
cleared, a new prosthesis is inserted (18). In severe cases, two-step revision surgery is 
performed. This entails removal of the infected prosthesis and filling the area with an 
antibiotic-augmented cement spacer (13, 14). A new prosthesis is implanted only when the 
infection has been eradicated (18, 24). Apart from being a stressful experience, complications 
from PJIs are unpredictable, with a success rate ranging from 14 to 100% (19). 
 
Treatment of osteoarthritis (OA), a condition affecting more than one out of four elderly 
people, usually involves total hip arthroplasty (THA), i.e. the insertion of a metallic prosthesis 
into the proximal region of the femur, replacing the femur head and neck (5, 6). Although most 
THAs are successful, cases of PJI caused by a bacterial biofilm forming on the prosthesis and 
spreading to adjacent tissue, are frequently reported (7–10). In most cases, the infection is 
caused by strains resistant to multiple antibiotics, including methicillin (29). 
 
The effect of direct (as opposed to systemic) antibiotic treatment on bone formation and 
remodelling is largely unknown and has not been studied in depth. Bone marrow-derived 
mesenchymal stromal cells (bmMSCs) have traditionally been used as an in vitro model to 
study the differentiation and functions of osteoblasts (bone-forming cells). However, more 
recently, a distinct population of MSCs residing in the proximal end of the femur, near the hip 
joint, was identified and characterised (30). These proximal femur-derived mesenchymal 
stromal cells (pfMSCs) are phenotypically similar to bmMSCs, but functionally distinct, with 
decreased osteogenic potential and increased sensitivity to the cytotoxic effects of 
glucocorticoids (30). Given that this sensitive population of MSCs resides in the exact areas of 
bone tissue involved in THA, it is possible that THA failure may disproportionately affect these 
cells, resulting in progressive bone damage. In addition, the possible cytotoxic effects of 
aggressive antibiotic treatment on this MSC population may cause long-term damage to the 
integrity of the femoral bone, preventing full recovery from THA revision after PJI. 
 
The discovery of new antibiotics with a broad spectrum of bactericidal activity is of paramount 
importance. In the present study, we describe two xenocoumacin 2-like antibiotics and a novel 
broad-spectrum antimicrobial compound produced by a strain of X. khoisanae. We also 
describe the effect of the broad-spectrum antimicrobial compound on bone marrow cells.
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MATERIALS AND METHODS 
 
 
Materials. Bacterial growth medium was sourced from Biolab Diagnostics (Midrand, 
South Africa), unless stated otherwise. Trifluoracetic acid (TFA), XAD-16 beads, triethylamine, 
carboxymethyl resin and all constituents of osteogenic differentiation media were obtained 
from Sigma-Aldrich (Missouri, USA). All solvents were obtained from Merck-Millipore (St. 
Louis, Massachusetts, USA), unless stated otherwise. SepPak C18 Columns were obtained 
from Waters (Milford, Massachusetts, USA). PierceTM BCA Protein Assay Kit (BCA) was sourced 
from Thermofisher Scientific (Waltham, Massachusetts, USA). Dulbecco’s Modified Eagle 
Medium (DMEM), Penicillin/Streptomycin (Pen-Strep), trypsin and Hanks’ Balanced Salt 
Solution were obtained from Lonza (Basel, Switzerland). Fetal bovine serum (FBS) was sourced 
from Biochrom (Berlin, Germany) and collagenase I (#CLS1) was sourced from Worthington 
Biochemical Corporation (Lakewood, USA). Cell culture dishes were obtained from NEST 
Biotechnology (New Jersey, USA). Sodium pentobarbitone (Eutha-naze) was sourced from 
Bayer (Kempton Park, Gauteng, South Africa). All mass spectrometry analysis was done with 
the help of the Liquid Chromatography Mass Spectrometry (LCMS) unit of the Central 
Analytical Facility at Stellenbosch University. Unless otherwise stipulated water, used in 
experiments was of analytical grade. 
 
Bacterial growth conditions. A strain of X. khoisanae was isolated from a nematode- 
infected soil sample in the Western Cape. Soil, suspended in sterile water, was plated onto 
NBTA (Nutrient Agar supplemented with 0.025%, w/v bromothymol blue and 0.004%, w/v 
triphenyltetrazolium chloride, TTC) and incubated at 30℃ for at least 48 h. Phase I cells, 
identified by the formation of blue colonies with the uptake of TTC and considered infective 
(5), were selected for further research. Staphylococcus aureus Xen 31 (methicillin-resistant) 
and S. aureus Xen 36 (methicillin-sensitive) were cultured in Brain Heart Infusion (BHI) broth 
and streaked onto BHI agar. Tubes and plates were incubated at 37℃ for at least 24 h. 
 
Isolation and purification of antimicrobial agent. Xenorhabdus khoisanae was 
cultured in Tryptic Soy Broth (TSB) for 24 h at 30℃, and then streaked out onto Tryptic Soy 
Agar (TSA). A single colony was transferred to 10 ml TSB, which had been treated with XAD- 
16 beads (5 g/10 ml) for 30 min at 4℃ before autoclaving for 15 min at 121℃, and vortexed. 
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The cell suspension was then mixed with 5 g sterile XAD-16 beads, plated out onto TSA treated 
with XAD-16 beads (2%, w/v, agar; 150mm diameter plates) and incubated at 26℃ for 96 h. 
The XAD-16 beads were removed from the surface of the agar, using a sterile metal scraper 
and suspended in double-distilled water (ddH2O). The beads were washed with 30% (v/v) 
ethanol (25 ml/5 g beads). 
 
Hydrophobic compounds were eluted from the XAD-16 beads, using 80% (v/v) isopropanol 
containing 0.1% (v/v) TFA (80% ISO-TFA; 40 ml/5 g beads). Isopropanol was removed by 
evaporation under vacuum using a rotary evaporator (Rotavapor R-114, Büchi) connected to 
a water bath (Waterbath B-480, Büchi), and compounds were concentrated by freeze-drying. 
The freeze-dried crude extract was suspended in ddH2O and tested for antimicrobial activity 
against S. aureus Xen 31 and S. aureus Xen 36, respectively. Overnight cultures of the two 
strains (300 µl each) were inoculated into 30 ml melted BHI Agar (1%, v/v, agar, cooled to 
40℃), swirled and plated out. Wells were made into the solidified agar with a sterile glass 
Pasteur pipette (5 mm in diameter) and filled with 20 µl aliquots of each fraction. Plates were 
incubated at 37℃ for 24 h. A clear zone surrounding the well indicated antimicrobial activity. 
 
The hydrophobic crude extract was injected onto a Discovery BIO Wide Pore C18 HPLC column 
(10 µm, 250 x 10 mm, Sigma-Aldrich). The chromatographic system comprised of two Waters 
510 pumps, controlled by MAXIMA software. Injections were controlled manually. 
Absorbance were taken with a Waters 440 detector at 254 nm. An increasing linear gradient 
of 10% to 100% of solution B in solution A over 12 min (Solution A: de-ionized water containing 
0.1% TFA, v/v, and solution B: acetonitrile containing 0.1% TFA, v/v) was applied (Table S1). 
Fractions collected were concentrated by freeze-drying and antimicrobial activity confirmed 
as described elsewhere. Freeze-dried samples were suspended in sterile water and the protein 
content determined using the BCA protein assay according to the manufacturer’s instructions. 
The HPLC program used is shown in supplementary Table S1. 
 
Characterization. The net charge of the antimicrobial molecules eluted from the C18 
HPLC column was determined using the method described by Yadav and co-workers (38), but 
slightly modified. Carboxymethyl resin was swollen in ddH2O, packed into a column and 
activated with 2% (v/v) acetic acid. The column was washed with five volumes ddH2O and the 
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resin charged using five volumes 2% (v/v) triethylamine (TEA). Three millilitres (10 mg/ml) of 
the active fractions were loaded onto the packed column. Anionic molecules were eluted 
using one volume 2% TEA, followed by three volumes of ddH2O to collect all neutral molecules. 
Cationic molecules were eluted using 3 to 5 ml of 2% TEA. The antimicrobial activity of all 
fractions was tested as described elsewhere. 
 
Active fractions collected from the HPLC were analysed using a Waters Quadrupole Time-of- 
Flight Synapt G2 (Waters Corporation, Milford, USA) mass spectrometer. Ultra-high-pressure 
liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was used to record high-
resolution mass spectra. For direct mass analysis, 3 µl of the sample (250 µg/ml, dissolved in 
50% acetonitrile) was injected into a Z spray ionization source, and for UHPLC-MS analysis, 3 
µl of the sample was injected and separated on an UPLC C18 column (Acquity UPLC HSS T3, 1.8 
µm particle size, 2.1 x 150 mm, Waters Corporation, Milford, USA). The sample was separated 
using an increasing linear gradient of 30% to 60% solution B in solution A over 9 min (solution 
A: 0.1% formic acid and solution B: acetonitrile. The flow rate was 0.3 ml/min (Table S2). A 
capillary voltage of 2.5 kV, cone voltage of 15 V and source temperature of 120℃ were used for 
both direct Electrospray Ionization mass spectrometry (ESI-MS) and UHPLC-MS analyses. All 
data obtained were analysed using Masslynx software version 4.1 (Waters Corporation, 
Milford, USA). The novel antimicrobial compound, observed as peak C3 on HPLC (Fig 1), was 
provisionally labelled as rhabdin. 
 
Determination of MIC (minimum inhibitory concentration). Freeze-dried HPLC-
purified rhabdin was dissolved in sterile ddH2O and the concentration was determined using 
the BCA protein assay according to the manufacturer’s instructions. A micro-broth dilution 
assay, described by Andrews (31), was used to determine the MIC of rhabdin. Staphylococcus 
aureus Xen 31 and S. aureus Xen 36 were used as indicator strains. Overnight culture of the 
two strains were each adjusted to an optical density (OD) of 0.11 (600 nm). Different 
concentrations of the antimicrobial compound were added to each strain, to obtain a final 
volume of 200 µl and OD of 0.1, and changes in growth observed by recording absorbance 
readings at 600 nm, immediately after addition, and 6 h and 24 h later. 
 
Isolation and maintenance of MSC. Ethical clearance to use rats in preparing MSC was obtained 
Stellenbosch University  https://scholar.sun.ac.za
81  
from the Research Ethics Committee: Animal Care and Use of Stellenbosch University 
(clearance number: SU-ACUD15-00012). The rats (male Wistar, 12 weeks old, with an average 
body mass of 250 g) were housed at the Stellenbosch University Animal Facility and kept 
according to the guidelines of the South African Medical Research Council. They were fed ad 
libitum on standard laboratory chow and sacrificed with an intraperitoneal injection of sodium 
pentobarbitone (12 mg/kg body mass). 
 
Isolation of pfMSCs and bmMSCs was performed as described by Jacobs and co-workers (30). 
Femora were surgically removed and cleaned from muscle tissue using sterile gauze. The 
proximal regions of the femora were removed with sterile surgical side cutters, cut into 1 mm3 
fragments and digested in Hanks’ Balanced Salt Solution containing 0.075% (w/v) collagenase I 
and 1.5% (w/v) bovine serum albumin for 1 h at 37℃. The denuded bone fragments were 
washed five times with DMEM, seeded into a culture dish with isolation media (DMEM 
containing 1%, v/v, Pen-Strep, and 20%, v/v, FBS) and incubated at 37℃ for 24h. The bone 
fragments were then washed with sterile phosphate-buffered saline (PBS), retained in the dish 
and submerged in standard growth media (SGM: DMEM containing 1%, v/v, Pen-Strep and 10%, 
v/v, FBS) for 7 to 10 days to allow migration of pfMSC from the fragments. bmMSCs were flushed 
from bone marrow cavities with 9 ml (3 ml per flush) cell isolation media collected in a cell 
culture dish (100 mm diameter). pfMSCs and bmMSCs were cultured at 37℃ for 24 h in 95% 
humidified air and in the presence of 5% CO2. Sterile PBS at 37℃ was used to remove non-
adherent tissue and the media was replaced with SGM. 
 
Both cell types (pfMSCs and bmMSCs) were cultured to 80% confluence and then disaggregated 
with 1 ml 0.5% (w/v) trypsin and sub-cultured at a ratio of 1:4. All cell cultures were expanded 
to passage 3 before being used for further experiments. Cell growth media and treatments were 
replaced every 2-3 days. Cells were maintained at 37℃ in 95% humidified air containing 5% CO2 
and were isolated as described by Jacobs and co-workers (30). 
 
Cytotoxicity of antimicrobial compounds. MSCs at passage 3 were seeded into 12- well plates 
for crystal violet staining or 96-well plates for the MTT conversion assay, and grown until post-
confluence in SGM. For crystal violet staining, cells were treated with increasing concentrations 
of rhabdin (1xMIC = 3.5 mg/l; 2.5xMIC = 8.75 mg/l; 4xMIC = 14.0 mg/l) for 7 days, fixed with 70% 
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(v/v) ethanol, stained for 5 min with 0.01 % (w/v) crystal violet and washed three times with PBS. 
The cells were destained with 75% (v/v) ethanol and absorbance measured at 570 nm. For the 
MTT conversion assay, cells were treated as described for crystal violet staining, with a final 
volume of 100 µl media per well. The methodology for the assay was adapted from the protocol 
for the Sigma-Aldrich in vitro Toxicology Assay Kit (MTT-based, #TOX1). After 7 days of 
treatment with rhabdin, 10 µl of   5 mg/ml MTT stock solution (Sigma-Aldrich #M2128) dissolved 
in DMEM, was added to each well and the plates incubated for 2h at 37℃ in the dark. The colour 
reaction was stopped by adding 100 µl solubilization solution (10%, v/v, Triton X-100 diluted 
with 0.1 N HCL in anhydrous isopropanol) to each well. Samples were incubated on a plate 
shaker to dissolve the colour product, and solubilization was further aided by repeated mixing 
with a pipette. Colour development was quantified spectrophotometrically at 570 nm to 
determine cell viability. Background absorbance was determined at 690 nm, and subtracted 
from the A570 values. A combination of cycloheximide (10 µg/ml) and tumour necrosis factor-α 
(TNF-α) (5 ng/ml) was used as the positive control for cytotoxicity in bmMSCs, while 1 µM 
dexamethasone was used as the positive control for cytotoxicity in pfMSCs, as reported 
previously (30). All experiments were performed with quadruplicate biological repeats. 
 
MSC differentiation. For osteoblastic differentiation, bmMSCs and pfMSCs at passage 
3 were plated in 12-well culture plates and cultured in SGM until post-confluence. 
Differentiation was induced with osteogenic media (OM: SGM supplemented with 50 µM 
ascorbic acid, 10 mM β-glycerolphosphate and 10 nM dexamethasone) as described by Jacobs 
and co-authors (30). Differentiating cells were treated with increasing concentrations of 
rhabdin as described elsewhere, and results recorded after 7 days (bmMSCs) and 21 days 
(pfMSCs). The mineralized extracellular matrix of cells was stained with Alizarin Red S (ARS: 
Amresco, USA). Cells were washed with PBS, fixed with 70% (v/v) ethanol at 25℃ for 5 min, 
rinsed twice with water and subsequently stained with 40 mM ARS (pH 4.0 - 4.1). The bmMSCs 
were stained for 2-4 hours, after which excess stain was removed. The wells were washed three 
times with water, once with PBS and an additional three times with water. Bound stain was 
extracted using 10% (w/v) cetylpyridinium chloride (CPC) dissolved in 10 mM Na2HPO4 (pH 7.0) 
and quantified spectrophotometrically at 562 nm. The pfMSCs were stained overnight with ARS 
and washed as described for bmMSCs. As pfMSCs have an impaired mineralization response 
compared to bmMSCs (30), staining was quantified using image analysis, which is more sensitive 
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than CPC extraction. Stained culture wells were visualized by light microscopy at 10x 
magnification using an Olympus CKX41 microscope. For analysis of each well, four random 
images (one in each quadrant) were photographed. As all experiments were performed in 
triplicate wells, this resulted in 12 images being captured for each experimental condition per 
independent experiment. Image analysis was performed using ImageJ image analysis software 
(version 1.51 J8). Images were converted into red-green-blue stacks and analyses were 
performed in the green channel. The threshold value (T=90) was set to exclude any non-specific 
background staining and remained unchanged throughout. For each image, the percentage area 
stained was recorded and an average of the percentage area stained for the 12 images per 
condition was calculated. 
 
Statistical analysis. GraphPad Prism (version 5.01) was used for all statistical analyses 
and data were expressed as average ±standard deviation. One-way ANOVA and Dunnett’s post 
hoc test were used to analyse the data. When P < 0.05, the difference was considered to be 
statistically significant and indicated with an *. 
 
RESULTS 
 
 
Isolation, purification and MIC of antimicrobial compounds. Hydrophobic compounds 
extracted from the X. khoisanae culture separated into seven peaks when loaded onto the 
Discovery BIO Wide Pore C18 HPLC column (HPLC, Waters), as shown in Fig 1. Fractions from 
peaks C2, C3 and C4 were active against S. aureus Xen 31 and Xen 36. The MIC of fraction C3, as 
determined against both indicator strains, was 3.5 mg/l. 
 
Characterization of novel antibiotic. Antimicrobial compounds collected from peaks C2, C3 and 
C4 (FIG 1) were positively charged. Separation by UHPL-MS and UV-Spectrum analysis revealed 
the presence of an antimicrobial compound with an m/z value of 407 in peaks C2 and C4 (FIG 
2A and C). The fragmentation patterns of the antimicrobial compound in the two peaks were 
similar, yielding m/z values of 250, 232 and 158 (FIG 1S). The UV- Spectra of C2 and C4 were 
also similar, with a UV-max of 245 nm and 314 nm (not shown). The variation in hydrophobicity 
suggests that peaks C2 and C4 are two isomers of the same antimicrobial compound. The m/z 
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value of the antimicrobial compound in peaks C2 and C4 (407 m/z), fragmentation pattern and 
UV-Spectra are similar to that reported for xenocoumacin 2 (7). The antimicrobial compound 
from peak C3 contained a different parent ion, with a m/z of 671.413 (FIG 2) and a UV-max of 
239 nm and 296 nm (not shown). MS-MS analysis of the antimicrobial compound in peak C3 
indicated the presence of four fragments (473.275 m/z, 350.199 m/z, 268.227 m/z and 144.080 
m/z, FIG 3). Further research was conducted on the compound from peak C3, labelled as 
rhabdin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 1: The chromatogram elution profile of the antimicrobial compounds isolated from a strain 
of X. khoisanae. The crude antimicrobial eluent was loaded onto a Discovery BIO Wide Pore C18 
HPLC column and separated using a linear gradient of solution B in solution A from 10% to 100% 
over 12 min (Table S1). Seven peaks were collected, but only three peaks had antibacterial 
activity (Peak C 2, 
C 7 C 6 C 5 
C 3 
C 2 
C 1 
C 4 
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FIG 2: The LCMS spectrograms of peak C2, C3 and C4 (refer to the HPLC chromatogram in FIG 
1). The m/z [M + H+] is shown above each peak. The main component present in peak C2 has 
a m/z [M + H+] of 407.219 (panel A); in peak C3 has a m/z [M + H+] of 671.413 (panel B) and 
in peak C4 has a m/z [M + H+] of 407.220 (panel C). 
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FIG 3: The MS/MS fragmentation pattern of C3 (m/z = 671.413). Four main fragments 
formed, with m/z ratios of 473.275, 350.199, 268.226 and 144.080. 
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 Cytotoxicity. The cytotoxicity of rhabdin to rat MSCs was evaluated via crystal violet 
staining and the MTT conversion assay. Crystal violet stains all the cells present in the well 
(dead and alive), and therefore the MTT conversion assay was employed as a more sensitive 
indicator of cell viability and metabolic activity. At concentrations of 4 x MIC and 2.5 x MIC, 
rhabdin was cytotoxic to bmMSCs, while concentrations of 1 x MIC and lower (data not 
shown) were well tolerated by these cells (FIG 4A). The pfMSCs were more sensitive to 
rhabdin, with even 1 x MIC being cytotoxic to the cells (FIG 4B). The MTT assay (FIG 5) mostly 
supported the crystal violet staining results, with only a slight decrease observed in the 
metabolic activity for bmMSCs in the presence of 1 x MIC rhabdin (FIG 5A). 
 
 
 
 
pfMSC B bmMSC A 
FIG 4: The effect of rhabdin on the cell culture density of bmMSCs (left panel) and pfMSCs 
(right panel). Cells in SGM were treated for 7 days with various concentrations of rhabdin 
as indicated and expressed as fold-MIC. Positive controls for cytotoxicity were 10 µg/ml 
cycloheximide together with 5 ng/ml TNFα (CxT) for bmMSCs and 1 µM dexamethasone 
(Dex) for pfMSCs. The cultures were subsequently stained with crystal violet, the stain was 
extracted and quantified spectrophotometrically at 570 nm. Values for control (SGM-
treated) wells were set as 100%. The graph represents the data of n = 2 each for 4 x MIC 
and 2.5 x MIC of rhabdin. The rest of the data represents n = 4. A post hoc Dunnet test was 
done with SGM as control. Statistical significance (p < 0.05) is indicated with *. 
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FIG 5: The effects of rhabdin on the metabolic activity of bmMSCs (left panel) and pfMSCs (right 
panel). Cells in SGM were treated for 7 days with various concentrations of rhabdin expressed 
as fold-MIC. Positive controls for cytotoxicity were 10 µg/ml cycloheximide and 5 ng/ml TNFα 
(CxT) for bmMSCs and 1 µM dexamethasone (Dex) for pfMSCs. Cell viability was measured via 
an MTT conversion assay and intensity of the colour product was measured at 570 nm. Values 
for control (SGM-treated) cells were set as 100%. No data is available for 4 x MIC and 2.5 x MIC 
rhabdin since complete cell death occurred within 24h. The graph represents data of n = 4. A 
post hoc Dunnet test was done with SGM as control. Statistical significance (p < 0.05) is 
indicated with *. 
 
 
The effects of rhabdin on the osteoblastic differentiation of MSCs. ARS stain was used 
to visualize the mineralized extracellular matrix that forms during osteoblast differentiation. 
The extracellular matrix of bmMSCs was completely mineralized after 7 days of OM treatment, 
while pfMSCs formed individual mineralized nodules after 21 days of OM treatment. Rhabdin 
at 1 x MIC appeared to induce a slight increase in mineralization in bmMSCs, although in 2 out 
of 7 bmMSCs isolates tested, rhabdin at 1 x MIC was toxic in the presence of OM (FIG 6A). 
Rhabdin at concentrations of 1 x MIC and upwards was cytotoxic to OM-treated pfMSCs, 
consistent with our observations in undifferentiated pfMSCs (FIG 4, data not shown for 
osteoblastic differentiation of pfMSCs). 
A bmMSC B pfMSC 
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DISCUSSION 
 
In the present study, we describe the purification and partial characterization of a novel 
antimicrobial compound, provisionally labelled rhabdin, isolated from X. khoisanae, and with 
activity against methicillin-resistant and methicillin-sensitive strains of S. aureus. As these 
organisms are most often the cause of antibiotic-resistant PJI after THA surgery (28), it is 
imperative that new infection control strategies are developed. However, the effects of 
aggressive antibiotic treatment on the surrounding bone tissue need to be taken into account 
when such strategies are considered. 
 
Xenorhabdus spp. are known to produce a wide variety of antimicrobial agents (7–10, 12, 32, 
33). Although most antimicrobial compounds produced by Xenorhabdus bacteria are small 
molecules like indole derivatives, iodinine, phenetylamides and benzylideneacetone, some 
more complex compounds have been identified, including xenorhabdins, xenorxides and 
xenocoumacins (33). The first Xenorhabdus antibiotic, produced by X. bovienii, was described 
by Paul et al. in 1981 (34). This was followed by the discovery of xenorhabdins and 
bmMSC 
FIG 6: The effect of rhabdin on osteoblastic differentiation of bmMSCs. The ARS stain was 
extracted and quantified spectrophotometrically. Cells treated with control media (SGM 
plus 0.1%, v/v, ethanol) did not form any mineral deposits. The graph represents data of n 
= 7. All data were compared to OM, which was set as 100%. Statistical significance 
(p < 0.05) is indicated with an *. 
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xenocaumacins by McInerney et al. in 1991 (7, 8). Xenocoumacins are benzopyran-1-one 
derivatives, produced by a polyketide synthase (PKS) / nonribosomal peptide synthase (NRPS) 
system and are known to form one of two fragments with a m/z ratio of 250 or 268, 
respectively (35). The first xenocoumacin was isolated from X. nematophilia A11, with six 
different xenocoumacins that are known to date. Xenocoumacins 1 and 2 are produced by X. 
miraniensis and X. nematophilia, while xenocoumacins 3 to 6 are produced by X. nematophilia 
and X. kzodoii (35). This is the first article to report xenocoumacin 2 production by X. 
khoisanae. A second antimicrobial compound, produced by the X. khoisanae strain, was also 
identified (m/z [M + H+] 671.413) and provisionally labelled as rhabdin. This antimicrobial had 
a somewhat similar, yet distinct, fragmentation profile as the xenocoumacins, indicating that 
rhabdin might be part of the same family as the xenocoumacins, but further studies are 
required to determine the structure of rhabdin. 
 
Despite their recognized antibacterial activity, little is known about the cytotoxicity of 
antibiotics produced by Xenorhabdus spp. As a first step in evaluating the possible effects of 
rhabdin on bone tissue, we assessed the cytotoxic and anti-osteoblastic effects of rhabdin on 
cultured bmMSCs and pfMSCs. Rhabdin was found to be cytotoxic at 1 x MIC in pfMSCs, and 
at 2 x MIC in bmMSCs, but had no anti-osteoblastic effects at 1 x MIC in bmMSCs. We observed 
a minor discrepancy in the actions of 1 x MIC on bmMSCs between the crystal violet staining 
and the MTT conversion assay, with 1 x MIC resulting in a slight loss of metabolic activity as 
quantified with the MTT conversion assay, but not resulting in a loss of crystal violet staining. 
This is likely due to 1 x MIC rhabdin causing a decrease in metabolic activity in bmMSCs, but 
not sufficiently so to result in cell death. This notion is supported by the observation that 1 x 
MIC, did not have anti-osteoblastic effects, in the majority of bmMSCs isolates tested. 
However, our results in pfMSCs indicate that rhabdin is unlikely to be safe to use as infection 
control to treat PJI, although this needs to be confirmed in an in vivo system. In addition, 
consistent with earlier published findings on sensitivity to glucocorticoids (30), pfMSCs were 
more sensitive than bmMSCs to the cytotoxic effects of rhabdin. Rhabdin at 1 x MIC induced 
a small (but not statistically significant) increase in mineralization in OM-treated bmMSCs. 
While an increase in local osteoblast function may contribute to bone strength and reduce the 
chance of osteoporosis after THA, it can also cause calcification of the joint, which may 
ultimately result in stiff joints and THA failure (36, 37). In vivo studies which include gene 
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expression analyses will help to shed light on the effects of rhabdin on bmMSCs and bone 
tissue. 
 
It is noteworthy that rhabdin exerts its cytotoxic effects on cultured mammalian cells at 
concentrations between 1 x MIC and 2 x MIC, while lower concentrations (0.25 x MIC) were 
found not to be cytotoxic (results not shown). From these observations, we can speculate that 
the cytotoxic and antimicrobial effects of rhabdin are mediated via a mechanism common to 
eukaryotic and prokaryotic cells. 
 
To conclude, our results indicate that our strain of X. khoisanae produces two types of 
antibacterial compounds, namely xenocoumacin 2 and a novel compound with a m/z ratio of 
671. This was the first study to report on the antimicrobial activity of X. khoisanae secondary 
metabolites. Further studies including H3-NMR are needed to determine the specific structure 
of rhabdin. Such studies may also pave the way for the identification or synthesis of 
Xenorhabdus antimicrobials with potent antimicrobial activity but no cytotoxicity against 
mammalian cells. While rhabdin was toxic to cultured bone-derived MSCs, this may be a cell- 
specific effect and warrants further investigation. 
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SUPPLEMENTARY INFORMATION 
 
 
TABLE S1: The elution program used to purify the crude antimicrobial isolated from a 
X. khoisanae strain using HPLC. A: 0.1% TFA prepared with analytical grade water. Solution B: 
90% acetonitrile in 0.1 % TFA (vol/vol/vol). 
 
Time A% B% Walters Curve 
0 90% 10% - 
0,5 90% 10% - 
12,5 0% 100% 6 
14 0% 100% - 
20 90% 10% 6 
25 90% 10% - 
 
 
TABLE S2: The elution program used to analyse the active fractions collected from the HPLC. 
Solution A: 0.1% (v/v) formic acid prepared with analytical grade water. Solution B: 90% 
acetonitrile in 0.1 % formic acid (vol/vol/vol) 
 
Time A% B% Walters Curve 
0 100% 0% - 
0,5 100% 0% - 
1 70% 30% 6 
10 40% 60% 6 
15 20% 80% 6 
15,1 100% 0% - 
20 100% 0% - 
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FIG S1: The MS/MS fragmentation pattern of C2 and C4 (m/z = 407.219). The parent ion in 
both peak C2 and C4 has a m/z of 407 and forms the same fragmentation pattern. Three 
main fragments formed namely 250.145, 232.134, 158.080.  
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Periprosthetic joint infections (PJI) are the major cause for total hip arthroplasty (THA) failures. 
In the majority of PJI cases, methicillin-resistant Staphylococcus aureus (MRSA) is the causative 
agent. Traditionally, MRSA is treated with vancomycin, a glycopeptide, that is administrated 
directly to the infected tissue or intravenously. The effect of applying vancomycin directly to 
bone tissue has not been studied in depth. In this study, we report on the cytotoxicity and 
osteogenic effects of vancomycin on rat-derived mesenchymal stem cells (MSCs). Two 
populations of MSCs were isolated from rat femora, i.e. bone marrow-derived mesenchymal 
stem cells (bmMSCs) and proximal femur-derived mesenchymal stem cells (pfMSCs). The cells 
were exposed to increasing concentrations of vancomycin, based on the minimum inhibitory 
concentration (MIC) of vancomycin against S. aureus Xen 31 (MRSA) and S. aureus Xen 36. High 
doses of vancomycin induced osteogenic differentiation in bmMSCs and had no cytotoxic side 
effects on bmMSCs. The pfMSCs were more sensitive and vancomycin caused a slight decrease 
in metabolic activity, as well as a decrease in osteogenic differentiation at 1 µg/ml and 5 µg/ml. 
These results suggest that directly applying vancomycin to an infected hip joint will not have 
any long-term detrimental effects, since the pfMSC population should recover after 
vancomycin cessation. 
 
INTRODUCTION 
 
 
The three major load bearing joints in the human body are the ankle, knee and hip (1). The 
human hip joint has a complex anatomical structure and is responsible for carrying the weight 
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of the upper body. During daily activity, the hip joint may experience loading forces up to 7 
times the body weight of the individual. This places the hip joint under immense mechanical 
pressure and is most likely the main cause for osteoarthritis (OA) in the joint (2). OA effects 
more than 25% of elderly people and is therefore a major cause of disability in this population 
group (3, 4). 
 
Currently, the only treatment available for severe hip OA is total hip arthroplasty (THA) (5). A 
metal prosthesis is inserted into the proximal region of the femur, replacing the proximal 
femur head and neck (6). Although THA is considered the most successful orthopaedic 
procedure of the past 120 years, and although advances in the field have significantly 
improved the risk profile associated with this procedure over the past five decades, 
complications still do occur (7–9). Periprosthetic joint infection (PJI) is the main cause for THA 
revision surgeries and is defined as bacterial contamination of the joint prosthesis and 
infection of the adjacent tissue (10). Most, if not all, PJI are caused by bacteria capable of 
forming biofilms (5). Many strains of these bacteria are resistant to a number of antibiotics 
(11), and treating PJI is therefore extremely difficult.  
 
The most common bacterial infections after THA are Gram-positive cocci. Staphylococcus 
aureus was isolated in 38% of all cases and 53% of the strains were methicillin-resistant (12). 
Failed treatment of PJI with conventional antibiotic regimes places an immense burden on 
medical professionals. Conventional treatments include intravenous administration of 
antibiotics for a maximum of 2 weeks, while aggressive treatment includes removal of the 
infected prosthesis and flushing of the infected joint (one-step revision surgery), followed by 
another 12 weeks on antibiotics. Once the infection has been cleared, a new prosthesis is 
inserted (13). In severe cases, a surgeon can opt for a two-step revision surgery. This entails 
initial removal of the infected prosthesis and insertion of an antibiotic-augmented cement 
spacer, followed by the implantation of a new prosthesis once the bacterial infection has been 
eradicated (13, 14). Both one-step and two- step revision surgeries can result in prolonged 
immobility, hospitalization and morbidity. The cost of treatment of a single episode of PJI 
can escalate to USD 50,000 or more (9). The increase in antibiotic resistance among hospital 
acquired infections, like PJI, have also increased the risk of failing to successfully treat PJI (15, 
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16). It is therefore clear that PJI presents a major challenge from both a health-care and 
economic perspective (17). 
 
Traditionally, methicillin-resistant Staphylococcus infections are treated with vancomycin (18). 
Vancomycin is either administered intravenously or directly to the infected site, by means of 
antibiotic-loaded cement spacers (19–21). The effect of direct (as opposed to systemic) 
vancomycin treatment on bone formation and remodelling is largely unknown. The effect of 
pharmaceutical drugs on bone formation and remodelling is traditionally evaluated in vitro 
with bone-marrow derived mesenchymal stems cells (bmMSCs). Recently, Jacobs and co- 
authors (22) reported on a second mesenchymal stem cell population in the femur, isolated 
from the proximal end of a femur. Although these proximal femur mesenchymal stem cells 
(pfMSCs) are phenotypically similar to bmMSCs, they are functionally distinct, with increased 
glucocorticoid sensitivity and a reduced osteoblastic differentiation potential. Since pfMSCs 
are located at the proximal end of femurs, this is also the exact area of tissue in contact with 
the prosthesis. Thus, direct application of vancomycin to pfMSCs could directly affect the 
success of THA revision surgeries. In the present study, we evaluate the cytotoxic and 
osteogenic effects of vancomycin on rat-derived mesenchymal stem cells. 
 
MATERIALS AND METHODS 
 
 
Materials. Bacterial growth medium was sourced from Biolab Diagnostics (Midrand, 
South Africa), unless stated otherwise. All constituents of osteogenic differentiation media 
were obtained from Sigma-Aldrich (Missouri, USA). Dulbecco’s Modified Eagle Medium 
(DMEM), Penicillin/Streptomycin (Pen-Strep), trypsin and Hanks’ Balanced Salt Solution were 
obtained from Lonza (Basel, Switzerland). Fetal bovine serum (FBS) was sourced from 
Biochrom (Berlin, Germany) and collagenase I (#CLS1) was sourced from Worthington 
Biochemical Corporation (Lakewood, USA). Cell culture dishes were obtained from NEST 
Biotechnology (New Jersey, USA). Sodium pentobarbitone (Eutha-naze) was sourced from 
Bayer (Kempton Park, Gauteng, South Africa). 
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Determination of MIC (minimum inhibitory concentration). A micro-broth dilution 
assay, described by Andrews (23), was used to determine the MIC of vancomycin. 
Staphylococcus aureus Xen 31 and S. aureus Xen 36 were used as indicator strains. Indicator 
strains from an overnight culture, cultivated at 37℃, were streaked out onto Brain Heart 
Infusion (BHI) agar and incubated for 24 h at 37℃. A singly colony was inoculated into BHI 
broth and incubated for 18 h at 37℃. Overnight culture of the two strains were both adjusted 
to an optical density (OD) of 0.1 (600 nm). Different concentrations of vancomycin were added 
to each strain (final volume of 200 µl) and changes in growth observed by recording absorbance 
readings at 600 nm, immediately after addition, and 6 h and 24 h later. 
 
Isolation and maintenance of MSC. Ethical clearance, clearance number: SU-ACUD15- 00012, 
to conduct experiments involving animals was granted by the Research Ethics Committee: 
Animal Care and Use of Stellenbosch University as part of a parent study group led by Prof 
William Ferris of the Department of Medicine, Stellenbosch University. The cells were isolated 
from Wistar rats’ femora and used for various sub-projects of this parent study. Adult Wistar 
rats (male, 12 weeks old, with an average body mass of 250 g) were fed ad libitum on standard 
laboratory chow and housed at the Stellenbosch University Animal Facility. Rats were kept 
according to the guidelines of the South African Medical Research Council.  
 
Isolated mesenchymal stem cells (MSCs) were maintained at 37℃ in 95% humidified air and in 
the presence of 5% CO2. Isolation was performed as described by Jacobs and co- authors (22). 
Femora of rats, sacrificed with an intraperitoneal injection of sodium pentobarbitone (12 
mg/kg body mass), were surgically removed and cleaned from any residual muscle tissue using 
sterile gauze. Proximal regions of the femora were removed with sterile side cutters, cut in 1 
mm3 fragments and digested in Hanks’ Balanced Salt solution containing 0.075% (w/v) 
collagenase I and 1.5% bovine serum albumin for an hour at 37℃. The denuded bone 
fragments were washed five times with DMEM, seeded into a culture dish (Ø100), immersed 
with isolating medium and incubated overnight at 37℃ in 95% humidified air containing 5% 
CO2. This was followed by rinsing the bone fragments with warm sterile phosphate-buffered 
saline (PBS ;37℃). The fragments were submerged in standard growth medium (SGM: DMEM 
containing 1% Pen-Strep and 10% FBS) for 7 to 10 days to allow migration of pfMSCs from the 
fragments. bmMSCs were flushed from the femora bone marrow cavities with cell isolation 
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medium (DMEM containing 1% Pen-Strep and 20% FBS), collected in a cell culture dish (Ø 100) 
and cultured at 37℃ for 24 h in the presence of 5% CO2 and 95% humidified air. Non-adherent 
material was removed after 24 h using warm sterile PBS (37℃) and the adherent cells 
submerged in SGM. Isolated cells were cultured to 80% confluence and disaggregated with 1 
ml 0.5% (w/v) trypsin added to 9 ml cells and sub- cultured at a ratio of 1:4. Cells were 
expanded to passage 3 before being used for further experiments and SGM with and without 
treatment compounds were replaced every 2-3 days. 
 
Cytotoxicity of vancomycin. Isolated MSCs at passage 3 were seeded into 12-well 
plates for crystal violet staining or 96-well plates for the MTT conversion assay, and grown 
until post-confluence in SGM. A combination of cycloheximide (10 µg/ml) and tumour necrosis 
factor-α (TNF-α; 5 ng/ml) was used as the positive control for cytotoxicity in bmMSCs, while 1 
µM dexamethasone (Dex) was used as the positive control for cytotoxicity in pfMSCs, as 
reported previously (22). For crystal violet staining, cells were treated with increasing 
concentrations of vancomycin (1 x MIC= 5 mg/ml; 4 x MIC = 20 mg/ml) as determined by the 
MIC, described elsewhere. Cells were cultured for 7 days, replacing media and treatments 
every 2-3 days, fixed with 70% (v/v) ethanol, stained for 5 min with 0.01% (w/v) crystal violet 
solution and rinsed three times with PBS. Crystal violet was extracted with 75% (v/v) ethanol 
and absorbance measured at 570 nm. 
 
 For the MTT conversion assays, cells were treated as described for crystal violet 
staining, with a final volume of 100 µl per well. The methodology for the assay was adapted 
from the protocol for the Sigma-Aldrich in vitro Toxicology Assay Kit (MTT-based, #Tox1). After 
7 days of treatment with vancomycin, 10 µl of 5 mg/ml MTT stock solution (Sigma-Aldrich 
#M2128), dissolved in DMEM, was added to each well. The plates were incubated for 2h at 
37℃ in the dark and the colour reaction stopped by adding 100 µl of solubilization solution 
(10% Triton X-100 diluted with 0.1 N HCL in anhydrous isopropanol) to each well. Solubilization 
was aided by incubating the 96-well plate on a plate shaker and repeated mixing with a 
pipette. Colour development was quantified spectrophotometrically at 690 nm (background 
absorbance) and 570 nm, respectively. The absorbance values of the background (690 nm) 
were subtracted from the A570 values. All experiments were performed with quadruplicate 
biological repeats and triplicate technical repeats. 
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 MSC differentiation. Isolated MSCs at passage 3 were plated in 12-well culture plates 
and cultures in SGM until post-confluence as described elsewhere. Osteoblastic 
differentiation was induced with osteogenic media (OM: SGM supplemented with 50 µM 
ascorbic acid, 10 mM β-glycerolphosphate and 10 nM dexamethasone) as described by Jacobs 
and co-authors (22). Cells were treated with vancomycin as described elsewhere. 
Differentiation was evaluated by staining with Alizarin Red S stain (ARS: Amresco, USA) after 
7 days (bmMSC) or 21 days (pfMSC). Before staining with 40mM ARS (pH 4.0 – 4.1), cells were 
washed with sterile pre-warmed PBS, fixed for 5 min at 25 ℃ with 70% (v/v) ethanol and rinsed 
twice with sterile water. After staining for 2 to 4 hours (bmMSC), the excess stain was removed 
and cells were washed in triplicate with water, once with PBS and an additional three times 
with water. Bound stain was extracted using 10% (w/v) cetylpyridinium chloride (CPC) 
dissolved in 10 mM Na2HPO4 (pH 7.0) and quantified spectrophotometrically at 562 nm. 
pfMSCs were stained overnight with ARS and washed, as described for bmMSC. Since pfMSCs 
have reduced osteogenic potential, staining was quantified using image analysis. Images were 
captured using an Olympus CKX41 microscope (CKX41, CachN 10x0.25 PhP objective), fitted 
with a Canon EOS 600D camera at 10x magnification. Four random images (one in each 
quadrant) were taken of each well, resulting in 12 images per treatment since experiments 
were performed in triplicate. Images were analysed with ImageJ software (version 1.51 J8) 
and converted into red-green-blue stacks. Analyses were performed in the green channel. A 
threshold value of T=90 was used to exclude non-specific background staining and remained 
unchanged throughout. The percentage area stained was recorded and the average for the 12 
images per condition was calculated. 
 
Statistical analysis. GraphPad Prism (version 5.01) was used for all statistical analyses 
and data were expressed as average ±SD. One-way ANOVA and Dunnett’s post hoc test were 
used to analyse the data. When p < 0.05, the difference was considered to be statistically 
significant and indicated with an *. 
 
RESULTS AND DISCUSSION 
 
Vancomycin is commonly used to treat MRSA infections. MRSA has been found to be the major 
causative agent in PJI (12). The MIC of vancomycin against S. aureus Xen 31 (MRSA) and Xen 36 
Stellenbosch University  https://scholar.sun.ac.za
103  
was 5 µg/ml and 1 µg/ml, respectively. This indicates that S. aureus Xen 31 has reduced 
susceptibility for vancomycin. 
 
Vancomycin, a glycopeptide, inhibits cell wall synthesis by binding to the terminal D-Ala-D- Ala 
dipeptide of peptidoglycan units (24). The effect of directly applying vancomycin on bone 
tissue has not been studied in depth. In the present study, we evaluated the cytotoxicity and 
anti-osteogenic effects of vancomycin, a glycopeptide, on two populations of rat femora 
derived MSCs, the bmMSCs and pfMSCs. The cytotoxicity of vancomycin to rat MSCs was 
evaluated via crystal violet staining and the MTT conversion assay. Both methods are used 
since crystal violet stains all cells present in a well (dead and alive), while the MTT conversion 
assay is more sensitive and is used to indicate metabolic activity and cell viability. 
 
High doses of vancomycin had no cytotoxic effects on bmMSCs, (Fig 1A) and no significant 
difference was observed between the cells treated with 1 x MIC and 4 x MIC vancomycin. The 
same applies for pfMSCs (Fig 1B), since only Dex treated cells were significantly different from 
SGM treated cells. A slight increase in cell density is observed for pfMSCs treated with 1 x MIC 
vancomycin, but this increase is not significant. The MTT conversion assay (Fig 2) supports the 
crystal violet staining data, with no cytotoxic effects observed for bmMSCs and pfMSCs treated 
with the highest dose of vancomycin (4 x MIC). These results indicate that directly 
administrating vancomycin to an infected hip joint will not have a detrimental effect on the 
MSC populations present near the joint. 
 
Osteoblastic differentiation was evaluated by staining the mineralized extracellular matrix 
with ARS. The bmMSCs were fully differentiated after 7 days of treatment with OM, while 
pfMSCs formed individual mineralized nodules after 21 days of OM treatment. The 
osteoblastic differentiation results correspond with results obtained by Jacobs and co-authors 
(22). Osteoblastic differentiation in bmMSCs increased slightly, but not significantly, when 
treated with 4 x MIC vancomycin (Fig 3A). In contrast, pfMSCs treated with vancomycin 
showed significantly reduced osteoblastic differentiation (Fig 3B). This indicates that direct 
application of vancomycin to an infected hip joint will halt osteoblastic differentiation, but 
since vancomycin is not cytotoxic to pfMSCs, osteoblastic differentiation of these cells will 
continue once vancomycin treatment is halted. 
Stellenbosch University  https://scholar.sun.ac.za
104  
FIG 1: The effect of vancomycin on bmMSCs (left panel) and pfMSCs (right panel) densities. 
Cells in SGM were treated for 7 days with different concentrations of vancomycin, as indicated 
and expressed as fold-MIC. Positive controls for cytotoxicity were 10 µg/ml cycloheximide 
together with 5 ng/ml TNFα (CxT) for bmMSCs and 1 µM dexamethasone (Dex) for pfMSCs. 
The cells were stained with crystal violet, the stain was extracted and quantified 
spectrophotometrically at 570 nm. Values for control (SGM-treated) wells were set as 100%. 
The graph represents data of n = 4. A post hoc Dunnet test was done with SGM as control. 
Statistical significance (p < 0.05) is indicated with *. 
FIG 2: The effect of vancomycin on the metabolic activity of bmMSCs (left panel, A) and 
pfMSCs (right panel, B). Cells in SGM were treated for 7 days with different concentrations 
of vancomycin expressed as fold-MIC. Positive controls for cytotoxicity were 10 µg/ml 
cycloheximide and 5 ng/ml TNFα (CxT) for bmMSCs and 1 µM dexamethasone (Dex) for 
pfMSCs. Cell viability was measured via an MTT conversion assay and intensity of the colour 
product was measured at 570 nm. Values for control (SGM-treated) cells were set as 100%. 
The graph represents data of n = 4. A post hoc Dunnet test was done with SGM as control. 
Statistical significance (p < 0.05) is indicated with *. 
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CONCLUSION 
Directly applying high doses of vancomycin to infected bone tissue in an effort to eradicate a 
persistent PJI may spare the surrounding bone tissue. Vancomycin exhibited mild anti- 
osteoblastic effects in differentiating pfMSCs, which may cause local loss of bone mineral 
density at vancomycin-treated sites, but we hypothesize that the absence of cytotoxicity of 
vancomycin on undifferentiated pfMSCs could result in the population of pfMSCs surrounding 
the affected area remaining intact, which will contribute to repair of the bone tissue upon 
cessation of vancomycin treatment. 
FIG 3: The effect of vancomycin on the osteoblastic differentiation of bmMSC (left panel, 
A) and pfMSC (right panel, B). Cells were treated with increasing concentrations of 
vancomycin. The formation of mineralized extracellular matrix was evaluated after 7 days 
(bmMSCs) or 21 days (pfMSCs). Cells treated with control media (SGM plus 0.1%, v/v, 
ethanol) did not form any mineralized deposits. The graph represents n = 7. All data were 
compared to OM, which was set as 100%. Statistical significance (p < 0.05) is indicated with 
an *. 
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Vancomycin is often used to treat infections caused by β-lactam-resistant bacteria. However, 
methicillin-resistant strains of Staphylococcus aureus (MRSA) acquired resistance to 
vancomycin, rendering it less effective in the treatment of serious infections. In the search for 
novel antibiotics, alternative delivery mechanisms have also been explored. In this study, we 
report on the encapsulation of vancomycin in PLGA [poly(DL-lactide-co-glycolide)] 
nanoparticles by electrospraying. The nanoparticles were on average 247 nm in size with small 
bead formations on the surface. Clusters of various sizes were visible under the SEM (scanning 
electron microscope). Vancomycin encapsulated in PLGA (VNP) was more effective in 
inhibiting the growth of S. aureus Xen 31 (MRSA) and S. aureus Xen 36 than unencapsulated 
vancomycin. Encapsulated vancomycin had a minimum inhibitory concentration  (MIC) of 1 
µg/ml against MRSA compared to 5 µg/ml of free vancomycin. At least 70% (w/w) of the 
vancomycin was encapsulated. Thirty percent of the vancomycin was released within the first 
144 h, followed by slow release over 10 days. Vancomycin encapsulated in PLGA nanoparticles 
may be used to treat serious infections. 
 
INTRODUCTION 
 
 
Nanomedicine is a rapidly expanding field, with the main focus on developing nanosized 
colloidal drug delivery vehicles. Nanoparticles, microparticles and nanofibers of various 
shapes are produced from polymers, metals (e.g. silver) and fatty acids (1). Polymeric 
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nanoparticles are well known for their ability to enhance the efficacy of drugs and improve 
drug circulation in vivo (2). The majority of polymer nanoparticles are constructed from 
biodegradable poly(ester) polymers, such as poly(lactide), poly(glycolide) and PLGA (3–5). The 
ease at which the hydrophobic characteristics of PLGA are manipulated, and the fact that it 
has been classified as safe, render this type of polymer ideal for the development of colloidal 
drug delivery systems (6). 
 
Antibiotics that are toxic at concentrated levels, poorly soluble, temperature sensitive or 
degraded by proteolytic enzymes can now be delivered to infected areas in a protected 
(encapsulated) form. This allows pharmaceutical industries to explore the use of “outdated” 
antibiotics. Nanoantibiotics utilize slow release of the drug from the particle to extend the 
time period between administration and this improves patient compliance since less hospital 
visits are needed (7, 8). 
 
In 2007, a group of researchers led by Daniel Lim showed that antibiotics associated with 
nanoparticles had enhanced antimicrobial activity against resistant bacterial strains (9, 10). 
The first nanoantibiotic approved by the FDA was Abelcet®, a liposomal amphotericin B lipid 
complex used to treat fungal infections (11). Other researchers have followed their lead with 
encapsulation of ciprofloxacin, minocycline, ampicillin, polymyxin B and many more in various 
nanoparticle compositions (12–20). 
 
Since vancomycin is commonly used to treat MRSA, the recent discovery of vancomycin- 
resistant MRSA by Andrew Kirby shocked the medical industry (21). This resulted in numerous 
research groups investing time and money in the encapsulation of vancomycin in 
nanoparticles. 
 
Various techniques have been reported for encapsulating vancomycin in PLGA nanoparticles. 
In the majority of reports, vancomycin-loaded nanoparticles were fabricated using the double- 
solvent evaporation emulsification method (DSEE) (6, 22, 23). Disadvantages associated with 
DSEE are a low encapsulation efficiency and difficulty in controlling the size distribution of 
nanoparticles. In the present study, vancomycin is encapsulated in PLGA nanoparticles 
fabricated by electrospraying to enhance the activity of vancomycin against S. aureus Xen 31 
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and S. aureus Xen 36. 
 
MATERIALS AND METHODS 
 
 
Materials. Poly (DL-lactide-co-glycolide) (PLGA) was sourced from Evonik (Germany). 
Dimethylformamide (DMF) was acquired from Merck-Millipore (USA) and the PierceTM BCA 
Protein Assay Kit (BCA) was obtained from Thermofisher Scientific (USA). Dimethyl sulfoxide, 
D-α Tacopherol polyethylene glycol 1000 succinate (Vitamin E) and vancomycin hydrochloride 
was acquired from Sigma-Aldrich (Germany). Acetonitrile was sourced from Microsep 
(Germany) and bacterial growth medium was sourced from Biolab Diagnostics (South Africa), 
unless stated otherwise. All ultra- high-pressure liquid chromatography (UHPLC) analysis was 
done with the help of the Liquid Chromatography Mass Spectrometry (LCMS) unit of the 
Central Analytical Facility at Stellenbosch University. Unless stipulated otherwise all water 
used in experiments was of analytical grade quality. 
 
Production of nanoparticles. Vancomycin was encapsulated in PLGA nanoparticles to 
ensure slow and steady release of the antibiotic. A protocol adapted from Van Staden was 
used to produce the nanoparticles (24). PLGA was dissolved in DMF (15% w/v), and 
vancomycin dissolved in DMSO (50 mg/ml), was added to the solution to yield a final 
concentration of 5 mg/ml. The organic and aqueous phases were emulsified on a magnetic 
stirrer at 200 rpm. DMSO, without vancomycin, was added for un-associated nanoparticles 
(CNP). A sterile glass Pasteur pipette and high voltage supply was used to produce the 
nanoparticles (FIG 1). The anode was connected to a glass collector and the cathode inserted 
into the polymer solution. A constant potential difference of 15 kV was applied to the polymer 
solution and -5kV to the collector. The relative humidity was kept below 30% and the 
temperature at 25℃. Nanoparticles were scraped off the glass collector and stored for future 
use. 
 
 Drug loading capacity and efficiency. Five milligrams of nanoparticles was dispersed 
in 5 ml DMF and incubated overnight on a rotating wheel at 37℃. Samples were centrifuged 
at 1000 x g for 30 minutes (Sigma 3-18K, Scientific equipment specialists, USA) and the 
concentration of encapsulated vancomycin determined using a modification of the UHPLC 
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protocol described by Baranowska and co-authors (25). An increasing linear gradient of 10% 
to 90% solution B in solution A over 30 seconds (Solution A: de-ionized water containing 0,1% 
TFA, v/v and solution B: acetonitrile containing 0.1% TFA, v/v) was applied. Absorbance 
readings were taken at 280 nm. The drug loading capacity (DLC) and encapsulation efficiency 
(EE) of the nanoparticles were determined using the following equations: 
 
𝐷𝐷𝐷𝐷𝐷𝐷 =  𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑀𝑀𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑜𝑜𝑎𝑎𝑎𝑎𝑀𝑀𝑎𝑎 𝑎𝑎𝑎𝑎 𝑀𝑀𝑀𝑀𝑎𝑎𝑠𝑠𝑎𝑎𝑠𝑠
𝑇𝑇𝑜𝑜𝑎𝑎𝑀𝑀𝑎𝑎 𝑎𝑎𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑀𝑀𝑀𝑀𝑎𝑎𝑠𝑠𝑎𝑎𝑠𝑠
 𝑥𝑥 100       (1) 
 
𝐸𝐸𝐸𝐸 =  𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑣𝑣𝑀𝑀𝑎𝑎𝑎𝑎𝑜𝑜𝑎𝑎𝑚𝑚𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎 𝑀𝑀𝑀𝑀𝑎𝑎𝑠𝑠𝑎𝑎𝑠𝑠
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑀𝑀𝑎𝑎 𝑣𝑣𝑀𝑀𝑎𝑎𝑎𝑎𝑜𝑜𝑎𝑎𝑚𝑚𝑎𝑎𝑎𝑎𝑎𝑎 𝑀𝑀𝑎𝑎𝑎𝑎𝑠𝑠𝑎𝑎 𝑎𝑎𝑜𝑜 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑀𝑀𝑜𝑜𝑎𝑎𝑠𝑠𝑎𝑎𝑎𝑎𝑜𝑜𝑎𝑎
 𝑥𝑥 100     (2) 
polymer solution 
Collector 
0 - 5° 
15 kV 
Power supply 
Glass Pasteur pipette 
FIG 1: Diagram of the electrospraying setup used to produce PLGA nanoparticles. PLGA was 
dissolved in DMF (15% w/v) (organic phase), vancomycin was dissolved in DMSO (50 mg/ml) 
(aqueous phase). The organic and aqueous phase were emulsified and injected into the glass 
pasteur pipette. The anode was connected to the glass Pasteur pipette (15kV) and the cathode 
to a collector (-5Kv). The glass pasteur pipette was placed at an angle to allow flow of the 
emulsified solution. The relative humidity was kept below 30% and temperature at 25℃.  
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Characteristics. The hydrodynamic diameter of the nanoparticles was determined by 
using dynamic light scattering (DLS) instruments (Malvern zetasizer nano S series). Briefly, 1 
mg nanoparticles was dissolved in 1 ml DMSO (1 mg/ml). Samples were mixed continuously 
during particle size analysis to prevent aggregation. The samples were measured in triplicate 
and the hydrodynamic diameter of the nanoparticles calculated by the Stokes-Einstein 
equation, the polydispersity factors (µ2/Γ2) were calculated from the cumulative method. (µ2: 
the second cumulant of the decay function; Γ2: average characteristic line width). 
 
The morphology of the nanoparticles was analysed using a scanning electron microscope 
(SEM; Zeiss Merlin SEM). Nanoparticles were placed on a SEM carbon adhesive tape and 
coated with gold and visualized at 5kV. 
 
Minimum inhibitory concentration (MIC). Agar well diffusion was used to determine the MIC 
of the nanoparticles. The nanoparticles were suspended in agarose gel plugs (Cylindrical 
shaped disks, diameter = 5mm and height = 5mm) at various concentrations. Overnight 
cultures of S. aureus Xen 31 (MRSA) and S. aureus Xen 36 (300 µl) were inoculated into 30 ml 
melted Brain Heart Infusion (BHI) Agar (1%, w/v, agar, cooled to 40℃), swirled and plated out. 
A sterile glass Pasteur pipette (diameter = 5 mm) was used to make wells in the solidified agar. 
Cylindrical gel plugs with nanoparticles were inserted in the wells and the plates were 
incubated at 37℃ for 24 h. Zone size was measured and analysed using ImageJ image analysis 
software (version 1.51 J8). 
 
The micro-broth dilution assay (26) was used to determine the MIC of vancomycin against 
S. aureus Xen 31 and Xen 36. Vancomycin was dissolved in double distilled H2O. The 
Staphylococcal strains were incubated overnight in BHI broth at 37℃ and adjusted to an A600 
of 0.1 using fresh BHI broth. Various concentrations of vancomycin were added to each strain 
(final volume of 200 µl) and treated bacteria were incubated at 37℃. The change in growth 
was observed by recording absorbance readings at 600 nm. Absorbance readings were 
recorded immediately after addition, and 6 h and 24 h later. 
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 Drug release kinetics. A diffusion cell was produced using a 3-D printer (FIG 2). A 5 kDa 
MWCO PES ultrafiltration membrane separated the donor and acceptor compartments of the 
diffusion cell. The walls of the diffusion cell were constructed from acrylonitrile butadiene 
styrene (Z-ABS, Zortax). The donor compartment contained 10 mg of nanoparticles dispersed 
in 2.5 ml 0,3% (w/v) vitamin E and the acceptor compartment 15 ml of 0.3% (w/v) vitamin E. 
The acceptor compartment was stirred magnetically at 600 rpm. At predetermined sampling 
times 500 µl of vitamin E solution was removed from the acceptor compartment and replaced 
with 500 µl fresh vitamin E solution. Samples were analysed and quantified using a Waters 
UHPLC (CAF, Stellenbosch University), as described elsewhere. These values were converted 
to a percentage value with 0.293 mg/ml set as the maximum (7.338% of 4 mg/ml). 
 
 
 
Acceptor Reservoir 
Donor reservoir 
FIG 2: The reservoirs used to determine the release profile of the nanoparticles. A solution 
consisting of 0,3% (w/v) vitamin E and nanoparticles (10 mg/ml) were placed in the inside 
donor reservoir. The acceptor reservoir contained 0,3% (w/v) vitamin E solution. At 
predetermined time intervals, 500 µl was sampled from the acceptor reservoir and 
replaced with 500 µl fresh vitamin E solution. 
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RESULTS AND DISCUSSION 
 
 
Drug loading capacity and efficiency. The DLC of VNP produced with electrospraying was 
7.33% (w/w) and the EE% was 73.9%. The average DLC reported in similar studies is 30.38% 
(6, 23). The DSEE method appears to be superior to electrospraying, but in contrast to these 
results the EE% achieved with electrospraying is higher. This suggests that electrospraying is 
a more efficient method for encapsulation of water-soluble drugs in PLGA, since less 
vancomycin was wasted during nanoparticle formation. 
 
Characteristics of CNP and VNP. The mean hydrodynamic size of the CNP as determined 
by DLS was 384 nm with a polydispersity index of 0.212 (FIG 3A). While the mean 
hydrodynamic size of vancomycin associated nanoparticles (VNP) as determined by DLS was 
247 nm with a polydispersity index of 0.385 (FIG 3B). The size difference observed for the CNP 
vs the VNP could be due to an interaction between the vancomycin and the polymer, forming 
a denser polymer matrix and thus a smaller nanoparticle. When comparing the sizes of the 
nanoparticles on the micrographs, the same difference in size for CNP and VNP is observed 
thus supporting the DLS results (FIG 4). 
 
The polydispersity index of VNP, produced with electrospraying, is higher compared to those 
reported by Loftipour and co-authors (6, 23). This suggests that nanoparticles produced by 
DSEE are larger, with a mean size of 400 nm, and more uniform in size. In contrast to the DSEE 
method, the polydispersity index of PLGA encapsulated vancomycin produced with the 
nanoprecipitation method, is similar to that reported in this study (27). In contrast, the 
polydispersity index and mean hydrodynamic size of un-associated PLGA nanoparticles 
produced by DSEE as reported in two separate studies by García-Díaz (28) and Menale (29), 
were considerably smaller compared to results obtained in this study by electrospraying. Since 
the conventional setup uses a syringe pump to control the flow of the polymer solution (30), 
the higher polydispersity index in this study could be due to uneven flow of the polymer 
solution from the Pasteur pipette. 
 
The linked and rough surface structure of the nanoparticles can also be attributed to the 
electrospray setup, since with small modifications this setup is often used to produce 
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nanofibers (31). Nanofibers are long fibres with diameters less than 1000 µm and are 
produced by electrospinning. 
 
Minimum inhibitory concentration. The MIC of vancomycin against S. aureus Xen 31 
and S. aureus Xen 36, as determined by the micro-broth dilution assay, is 5 µg/ml and 3 µg/ml 
respectively, and the MIC of VNP for both indicator strains is 1 µg/ml. This indicates that by 
encapsulating antibiotics, their antimicrobial activity can be enhanced. This supports the 
results obtained by Daniel Lim (10). This is likely due to a higher concentration, compared to 
free-vancomycin, since the hydrophobic nanoparticles bind to hydrophobic chains present on 
the cell wall of pathogens. The vancomycin is released in closer proximity to the bacteria, thus 
no “dilution” effect is observed. Further studies are needed to elucidate the exact mechanism 
of action of PLGA encapsulated nanoparticles. 
 
Drug release kinetics. In an aqueous environment, therapeutic drugs encapsulated in 
PLGA are released via bulk erosion of the particle (6). The release rate of vancomycin from 
PLGA depends on the ratio of poly(lactide) (PLA) and poly(glycolide) (PGA), the higher the PLA 
concentration the more hydrophobic the particle thus the slower the release rate (32). 
Vancomycin release was monitored for 240 h (10 days) and followed first-order release. 
Within 24 h, 5 µg/ml vancomycin was released from the nanoparticles and detected in the 
acceptor reservoir; thus, nanoparticles are therapeutically active within 24 h. Only 50% (1.47 
mg vancomycin) of the total encapsulated vancomycin was released in 10 days, suggesting 
that these nanoparticles will stay therapeutically active for a minimum of 14 days. This 
indicated that antibiotic administration can be reduced to once every 2 weeks, thus increasing 
patient compliance and reducing hospitalization costs. A burst release was observed after 48 
h, rendering vancomycin PLGA nanoparticles perfect for use as a prophylaxis treatment to 
prevent post-surgical infections. 
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FIG 3: The hydrodynamic diameter distribution of a) un-associated nanoparticles (CNP) and 
b) vancomycin associated nanoparticles (VNP) as determined by DLS. Particles were 
dissolved in DMSO (1 mg/ml), mixed continuously and measured in triplicate. The 
hydrodynamic diameter was determined by the Stokes-Einstein equation. The mean size 
of CNP was 384 nm, with a polydispersity index of 0.212 and of VNP was 247 nm with a 
polydispersity index of 0.385. 
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FIG 4: SEM micrographs of un-associated nanoparticles (CNP) and vancomycin 
encapsulated nanoparticles (VNP). Micrographs A and B are at 5000 x magnification, 
Micrographs C and D are at 10 000 x magnification  and  micrographs E  and  F are  at  50 
000 x magnification. 
CNP VNP 
A B 
C D 
E F 
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CONCLUSION 
 
PLGA nanoparticles loaded with vancomycin were prepared by the electrospraying method. 
The antibacterial activity of free vancomycin and encapsulated vancomycin were compared in 
vitro. Results indicated that encapsulating vancomycin in PLGA nanoparticles improved the 
antibacterial activity of vancomycin against MRSA. VNP had a MIC of 1 µg/ml, even though 
only 7% of the total particle consisted of vancomycin. Further studies are needed to elucidate 
the exact mechanism of action, but one possibility is that the nanoparticle binds to the cell 
wall of the bacterium. This increases the effective concentration of vancomycin in close 
proximity to the target of inhibition (D-Ala-D-Ala terminal end of peptidoglycan). These results 
suggest that the pressure of antibiotic resistance can be partially alleviated by encapsulating 
antibiotics in nanoparticles. Another advantage of encapsulating antibiotics is targeted or 
location delivery, thus reducing the spread in antibiotic resistance and reducing the death of 
commensal bacteria seen with conventional administration of antibiotics. The VNPs and CNPs 
had a rough surface structure and were spherical in shape, showing that vancomycin had no 
influence on the shape of the particles. The polydispersity index of VNPs and CNPs was above 
0.2. We suggest using a syringe pump to improve size distribution. Vancomycin release was 
evaluated for 10 days; burst release was observed after 48 h and by the end of the assay only 
50% of the encapsulated vancomycin had been released. These results indicate that 
encapsulated vancomycin can be used as a prophylaxis treatment, preventing hospital 
acquired infections post-surger
FIG 5: The cumulative release rate of VNP as determined by UHPLV for 240 h (10 days). 
Release followed a first-order release rate and within 24h enough vancomycin was released 
to be deemed therapeutically active. 
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General discussion and conclusion 
 
Total hip arthroplasty (THA) is considered the most successful orthopaedic operation, with a 
failure rate of 5% (1). The major cause for early THA revisions is periprosthetic joint infections 
(PJI) (2), which places an immense burden on the medical industry. Methicillin-resistant 
Staphylococcus aureus (MRSA) is the main causative agent of PJI and is isolated from 19% of 
cases (3). Traditionally, vancomycin is used to treat MRSA infections, but Kirby and co-workers 
recently reported on the isolation of MRSA with reduced vancomycin susceptibility (4). This 
rise in antibiotic resistance has made it nearly impossible to treat these infections. Thus, the 
discovery of novel antibiotics with a broad activity spectrum is of utmost importance. Radical 
PJI treatment entails removal of the infected prosthesis, direct application of antibiotics to the 
infected tissue, followed by a 12-week antibiotic course and insertion of a new prosthesis once 
the infection has cleared (5). However, direct application (as opposed to systemic 
administration) of antibiotics on bone formation and remodelling has not been studied in 
depth. 
 
Prophylaxis treatment is suggested to reduce the occurrence of PJI (6). Traditionally drug 
impregnated cement was used in prophylactic treatment (7, 8), but the advances in 
nanotechnology has made it possible to encapsulate antibiotics in nanoparticles. Studies have 
also shown that by encapsulating antibiotics, their bio-absorption, antimicrobial activity and 
half-life can be improved (9). 
 
Characterization of Xenorhabdus khoisanae antibiotics 
 
Three antimicrobial agents were isolated from a X. khoisanae strain. Two were xenocoumacin-
2 like and one a novel antibiotic with a mass-to-charge (m/z) ratio of 671, designated rhabdin. 
Xenocoumacin-2 has previously been isolated from Xenorhabdus miraniensis and 
Xenorhabdus nematophilia (10, 11). This is the first report on the isolation of xenocoumacin- 
2 like antimicrobials from X. khoisanae. Rhabdin was analysed with ultra-high-pressure liquid 
chromatography coupled to electrospray ionization mass spectrometry (UHPLC-MS/MS). A 
MS/MS fragmentation profile was obtained, indicating the presence of four fragments with 
m/z ratios of 473, 350, 268 and 144. Antimicrobial studies revealed that rhabdin is active 
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against Staphylococcus aureus Xen 31 (methicillin-resistant) and S. aureus Xen 36 (methicillin- 
sensitive) at levels as low as 3.5 µg/ml (minimum inhibitory concentration = MIC). 
 
The cytotoxic and osteogenic effects of rhabdin were evaluated on two populations of rat 
derived femora mesenchymal stem cells (MSCs), bone marrow-derived mesenchymal stem 
cells (bmMSCs) and proximal femur-derived mesenchymal stem cells (pfMSCs). The second 
population, pfMSCs, was recently described by Jacobs and co-authors (12) as a phenotypically 
similar, but functionally distinct population of femora derived MSCs. This study revealed that 
rhabdin was cytotoxic to bmMSCs at levels exceeding 3.5 µg/ml, but pfMSCs were more 
sensitive as levels below 1 x MIC (3.5 µg/ml) was completely cytotoxic. Rhabdin had no anti-
osteogenic effects on bmMSC at 3.5 µg/ml. 
 
Although the toxicity and instability of rhabdin might impede the FDA approval of this 
antibiotic for use in PJIs, further cytotoxicity studies are needed to evaluate the potential of 
rhabdin in a clinical setting, especially since rhabdin is equally active against MRSA and 
methicillin-sensitive S. aureus. The cytotoxicity of rhabdin also indicates that it might have 
anti-cancer properties, but further studies are required to verify this claim. 
 
Cytotoxic and osteogenic effect of vancomycin 
 
 
Vancomycin, a glycopeptide, is commonly used to treat MRSA infections (13), yet no studies 
have been done on the cytotoxic and osteogenic effects of vancomycin on femora derived 
MSCs. In this study, we report that vancomycin had no cytotoxic effects on bmMSCs or pfMSCs 
at high doses (20 µg/ml), but had anti-osteogenic effects on pfMSC. 
 
Although vancomycin had anti-osteogenic effects, our study indicates that applying 
vancomycin directly to the infected bone tissue will not have any long-term negative effects, 
since the pfMSCs should recover once vancomycin treatment is stopped. 
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Nanoparticle encapsulation of vancomycin 
 
 
Vancomycin was encapsulated in PLGA nanoparticles by electrospraying and its effeciecy 
compared to vancomycin-free PLGA nanoparticles. The drug-loading content of the 
vancomycin nanoparticles (VNP) was 7.33%, while the encapsulation efficiency was 73.9%. 
This indicates that 100 mg of nanoparticles contains 7 mg of vancomycin and that 73.9% of 
the initial vancomycin was incorporated into the particle. The hydrodynamic diameter of the 
VNP was 247 nm, while the diameter of un-associated nanoparticles (CNP) was 384 nm. This 
size reduction is most likely due to an interaction between the vancomycin and polymer used. 
Antimicrobial studies indicated that encapsulated vancomycin (MIC = 1 µg/ml) was more 
antimicrobially active compared to free vancomycin (MIC= 5 µg/ml). Vancomycin release was 
monitored for 10 days and within the first 24 h, 5 µg/ml vancomycin was released from the 
nanoparticles. After 10 days, only 50% of the encapsulated vancomycin was released, 
indicating that VNP will stay therapeutically active for a minimum of 14 days. 
 
This study indicates that encapsulated antibiotics can be used in prophylactic treatments. One 
possibility is incorporating the nanoparticles in a specially designed prosthesis with micro- 
channels, fitted with a one-directional membrane. This would ensure the release of the 
encapsulated drug at the desired location and prevent removal of nanoparticles by circulation 
and macrophage engulfment, ultimately reducing the chance of THA failure due to infection. 
Although this study focussed on hip replacements and MRSA infections, the data can be 
applied to other joint replacement surgeries and infections. 
 
Conclusion 
 
 
In conclusion, the in vitro cytotoxicity assays showed that rhabdin is cytotoxic to bmMSCs at 
levels exceeding 3.5 µg/ml, but further in vitro studies on other cell lines is needed before 
rhabdin can be deemed toxic to humans. Further research is needed to determine the 
structure of rhabdin.  
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Vancomycin had no toxic effects on bmMSCs or pfMSCs, but had an anti- osteogenic effect on 
pfMSCs at low levels. The antimicrobial activity of vancomycin was enhanced by encapsulation 
in nanoparticles, indicating that vancomycin nanoparticles have potential to be used for 
prophylaxis treatment during THA. Further research and in vivo studies are needed to support 
the vancomycin findings obtained in this study. 
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